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Introduction
On September 15, 2019, Purdue Pharma L.P., along with its subsidiaries, declared Chapter 11
bankruptcy upon filing a voluntary petition with the United States Bankruptcy Court for the
Southern District of New York.1 This filing was spurred by the company’s desire to consolidate and
organize the tremendous number of lawsuits filed against it for its role in the opioid epidemic.2 This
paper briefly touches on the company’s actions leading to its filing before focusing on the
company’s post-petition actions.

1 Chapter 11 Voluntary Petition for Non-Individuals Filing for Bankruptcy, In re Purdue Pharma, Case No .19-23549
(Bankr. S.D.N.Y. Sept. 15, 2019) [https://perma.cc/WK7A-JWLS].
2 Jan Hoffman & Mary Williams Walsh, Purdue Pharma, Maker of OxyContin, Files for Bankruptcy, N.Y. TIMES, Sept. 15,
2019, https://perma.cc/6LTH-YENX.

5

Pre-Petition History
Company History
Purdue Pharma L.P. arose from the Purdue Frederick Company, founded in 1892 by medical
doctors John Purdue Gray and George Frederick Bingham.3 The Purdue Frederick Company began
by selling earwax removers and laxatives, until it was sold to brothers and medical doctors Raymond
Sackler and Mortimer Sackler in 1952.4 A third brother, medical doctor Arthur Sackler, held a onethird equity option in the company.5 Dr. Arthur Sackler was known for his advertising acumen,
which at times were blatantly deceptive.6 Together, the Sackler brothers amassed a fortune through
the production and advertising of pharmaceuticals.7
Eventually, the company headquartered in Stamford, Connecticut.8 Over the next several
decades Purdue Pharma began making opioid pain medication such as hydrocodone, oxycodone,
and fentanyl.9 In 1991, Purdue Pharma L.P. incorporated and focused its efforts towards the
manufacture and marketing of pain management medications.10

3 Ronald Chow, Purdue Pharma and OxyContin – A Commercial Success But Public Health Disaster, HARVARD PUB. HEALTH
(2020), https://perma.cc/CV7A-JUTZ.
4 Id.
5 Benjamin Sutton, Elizabeth A. Sackler Supports Nan Goldin in Her Compaign Against OxyContin, HYPERALLERGIC (Jan. 22,
2018), https://perma.cc/3GRZ-TGYC.
6 Patrick Radden Keefer, The Family That Built An Empire of Pain, THE NEW YORKER (Oct. 23, 2017),
https://perma.cc/UUJ5-3XRK.
7 Id.
8 Id.
9 Chow, supra note 3.
10 Id.
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Purdue’s False Claims and Marketing regarding OxyContin
In 1995, Purdue Pharma introduced OxyContin to treat chronic pain.11 OxyContin is a pain
medication drug that contains oxycodone as its active ingredient.12 In its marketing for OxyContin,
Purdue Pharma made several false claims relating to its efficacy and addictive nature.
The company marketed OxyContin as a “wonder drug” due to its extended-release formula
and non-addictive quality.13 The extended-release formulation was helpful as it precluded patients
from having to wake up during the night or interrupt their day to take pain medication.14
Additionally, Purdue claimed OxyContin’s addictive potential was “small” or “less than 1%.”15
However, OxyContin’s twelve-hour relief claim did not hold true.16 Given that the
medication’s effects was advertised to last twelve hours, patients were only intended to take the
medicine twice a day. However, because OxyContin’s effects would often cease before the twelvehour mark (as evidenced in Purdue’s own clinic trials), many patients being treated with the drug
would often ask for medication prior to their next scheduled dose or supplement with other
painkillers.17 Despite the company knowing the twelve-hour claim was false, Purdue Pharma sought
FDA approval for OxyContin as a twelve-hour effective analgesic, eventually producing
advertisements touting this duration.18
Purdue also trained its sales staff to represent that OxyContin’s risk of addiction was low,
especially compared to other palliative medication.19 In reality, the risk for addiction among patients
with chronic pain was as high as 50%, with many studies reporting abuse in up to 20-40% of

Id.
Similarities and Differences Between Oxycodone and Oxycontin, AMERICAN ADDITION CENTERS, (last updated Jan.
11, 2021), https://perma.cc/L4YG-W64C.
13 Chow, supra note 3.
14 Id.
15 Id.
16 Id.
17 Id.
18 Chow, supra note 3.
19 Id.
11
12
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patients.20 These claims bolstered OxyContin’s sales to generate $2.8 billion in revenue for Purdue
from 1995 and 2001, accounting for 90% of the company’s sales at one point.21

20 Id. See e.g., Chabal et al, Prescription opiate abuse in chronic pain patients: clinic criteria, incidence, and predictors, NAT’L LIBR. OF
MED. (Jun. 1997) https://perma.cc/9XMV-K7AD.
21 Barry Meier, In Guilty Plea, OxyContin Maker to Pay $600 Million, N.Y. TIMES (May 10, 2007), https://perma.cc/AM4EMRQY.
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The Opioid Crisis
Due to Purdue’s (at the time unknown) fraudulent claims abouts OxyContin’s risk for abuse,
physicians began being prescribing the drug more readily.22 Additionally, patients discovered that
the pills could be crushed to bypass the time release nature of OxyContin’s casing and achieve a
more instant effect, comparable to morphine.23
With medical doctors (over-) willingness to prescribe the medication coupled with a growing
demand for the drug, OxyContin abuse began to rise. The first trends of abuse were noticed
regionally, in areas such as Maine, West Virginia, eastern Kentucky, southwestern Virginia, and
Alabama.24 In these areas between 1998-2000, non-OxyContin oxycodone was prescribed at 2.5 to 5
times the national average; by 2000, these areas were prescribing OxyContin at 5-6 times the
national average.25 Eventually, this trend spread nationally, between 2002 and 2004 lifetime
nonmedical use of OxyContin increased from 1.9 million people to 3.1 million people.26 This surge
in OxyContin abuse spurred abuse of other opioids including fentanyl, morphine, and oxycodone.27
Opioids became second only to marijuana for illicit drug abuse with overdose deaths climbing
dramatically.28 Opioid-related overdoses increased from approximately 17,500 in 2006 to 42,000 in
2016.29

Chow, supra note 3.
Id.
24 Art Van Zee, MD, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy, 99(2) AMERICAN
J. PUB. HEALTH, 221-227 (Feb. 2009), https://perma.cc/6FE4-T2WH.
25 Id.
26 Id.
27 Id.
28 Id.
29 Qiushi Chen, PhD et al., Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States, JAMA
NETWORK OPEN (Feb. 1, 2019), https://perma.cc/3WCV-RKCP. Estimates about the actual death toll vary.
22
23
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Government efforts to combat the opioid crisis began in the early 2000s when agencies
noticed the alarming trend of OxyContin abuse. Health agencies began pushing tactics such as
better addiction prevention, treatment, and recovery30 while attorneys general pursued legal action.

See e.g., 5-Point Strategy To Combat the Opioid Crisis, U.S. DEPT’ OF HEALTH AND HUMAN SERV.,
https://perma.cc/ZBF7-XGSN (last reviewed Jan. 21, 2021).
30
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Events Leading to Bankruptcy
Litigation
In 2007, the attorney general of Connecticut commenced a twenty-six state lawsuit against
Purdue on account of the company’s fraudulent marketing.31 Purdue and three of its executives
pleaded guilty to criminal charges of misleading regulators, doctors, and patients about OxyContin’s
risk of addiction and potential for abuse.32 The Company agreed to end some of its controversial
drug marketing and pay $600 million in fines and other payments, with three of its executives also
paying a total of $34.5 million in fines.33
In May 2018, six states filed lawsuits against Purdue over misleading marketing tactics of
OxyContin which fueled the opioid epidemic.34 In June 2018, the Attorney General for
Massachusetts personally named Purdue executives and directors, including members of the Sackler
family, for their role in the marketing of OxyContin and its impact on the opioid epidemic.35
Following this, many other states and hundreds of cities have brought suit against the Sacklers.36
Eventually, more than 2,000 lawsuits were joined under the National Prescription Opiate
Litigation, a multidistrict litigation proceeding.37 In this litigation several states, cities, Native
American tribes, and other parties allege that the manufacturers of prescription opioids (including

Keefe, supra note 6.
Meier, supra note 20.
33 Id. See also Erk Ofgang, Purdue Pharma and OxyContin: A Timeline, CONN. MAG. (Oct. 24, 2019),
https://perma.cc/MDU5-9QN9 (estimating that by 2016 Purdue had earned more than $36 billion in revenue from
OxyContin).
34 John C. Moritz, 6 states sue maker of OxyContin as they battle expenses, human costs of opioid crisis, USA TODAY (May 15,
2018), https://perma.cc/S752-5BF8 (Attorneys General representing Nevada, Texas, Florida, North Carolina, North
Dakota, and Tennessee filed suit; Florida and North Dakota were not part of the 2007 settlement.).
35 Attoreny General’s Office Lawsuit Against Purdue Pharma and its Executives and Directors, MASS.GOV, https://perma.cc/S7525BF8 (last visited Apr. 17, 2021).
36 Id.
37 MDL 2804 Opiate Litigation, U.S. DIST. CT. N. DIST. OF OHIO, https://perma.cc/75EE-6EGF (last visited Apr. 17,
2021).
31
32
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Purdue) grossly misrepresented the risks of long-term use of those drugs for persons with chronic
pain which, in part, contributed to the current opioid epidemic.38

38

Id.
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Purdue files Bankruptcy
This massive wave of litigation prompted Purdue to seek relief in Chapter 11. In its
Debtor’s Information Brief, the Debtors point to the over two thousand lawsuits alleging it
deceptively marketed OxyContin as non-addictive which helped create a national opioid addiction
crisis.39 Purdue hopes to consolidate these litigants into a single class of creditors, via Chapter 11, to
adjudicate their claims and provide finality to its liability.40
The Debtors emphasized that the thousands of lawsuits pending against it span dozens of
state and federal jurisdictions, were brought by diverse plaintiffs, existed at various procedural
stages, and hosted a wide array of claims and legal theories despite common legal and factual
defenses.41 The Debtors illustrated that they had reached a tentative settlement with a critical mass
of plaintiffs.42 However, in order to lump in the outlying plaintiffs and for the benefit of the
estate—and its stakeholders—the debtors believed a bankruptcy was necessary to create a single
class of litigants.43
The Debtors contended that absent relief from the bankruptcy court, its estate would be
eroded by litigants.44 The Debtors claimed they spent approximately $63 million for legal
representation, expert fees, and other expenses related to defending the litigation through the first
half of 2019.45 The Debtors expected to spend approximately $121 million by the end of 2019, and
a total of $263 million on legal and related professional costs to litigate these actions to conclusion.46

39 Id. at 4. Debtors emphasized that they lack significant debt or past due obligations that traditionally spur Chapter 11
Bankruptcy.
40 Id. at 52.
41 Id. at 36-41. Debtors also highlight that the only case which has rendered a verdict was not held against them. Id. at
41-44.
42 Id. at 44.
43 Id. at 44-45
44 Id. at 45.
45 Id. 45-46.
46 Id.
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Additionally, the Debtors pointed to the significant disruption the ongoing litigation was
causing to the company’s human capital.47 Purdue Pharma eliminated approximately 67% of its
employees since 2017 and the remaining employees’ focus was pulled away from their main
corporate responsibilities towards preparing for and participating in the ongoing litigation.48
Finally, the Debtors contended that this litigation had caused or exacerbated operational
challenges for its vendors, suppliers, and other entities necessary to its operations.49 Further, the
negative public sentiment garnered from the lawsuits discouraged vendors from partnering with the
Debtors. Collectively, these challenges affected the Debtors’ operations and degrades their ability to
conduct business. The Debtors illustrated this degradation by pointing to its declined opioid sales
from $2.2 billion in 2010 to $975 million by 2018.50

Id. at 46.
Id.
49 Id. at 46-47.
50 Id. at 47.
47
48
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Applications to Retain Professionals
Purdue Pharma applied for the authority to employ and retain Davis Polk & Wardwell
(“Davis Polk”) as attorneys for the Debtors nunc pro tunc to the petition date.51 This means the
Debtors were asking the court for the authority to retain Davis Polk’s services moving forward and
also asking the court to retroactively approve of the Debtors’ employment of Davis Polk during the
time between when the petition was filed and the application. Section 327(a) allows the Debtor in
possession of the bankruptcy assets (the “DIP”) to employ attorneys and other professionals with
the court’s approval.52 Rule 2014(a) requires the DIP to file an application to the court to employ
professionals and Rule 2016(b) requires disclosure of the fees promised or paid to the
professionals.53
The Debtors sought to employ Davis Polk as lead restructuring counsel because of the
firm’s “extensive experience and knowledge in both corporate transactional work and litigation,” 54
as well as its recent involvement in a wide variety of chapter 11 cases.55 The Debtors asserted that
Davis Polk was intimately familiar with its business and financial affairs, was well-qualified to
represent the Debtors, and that retaining different restructuring counsel would resulted in undue
prejudice and expense to the estate and all parties involved because new counsel would have needed
extra time to catch up.56 Davis Polk would provide legal services to the Debtors including preparing
pleadings for the Debtors, counseling the Debtors in their rights and obligations as DIP, providing

51 Application of Debtors for Authority to Employ and Retain Davis Polk & Wardwell LLP as Attorneys for the
Debtors Nunc Pro Tunc to the Petition Date 1.pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed
Sept. 15, 2019), [hereinafter “Application to Employ Davis Polk”], https://perma.cc/S5D7-55XN.
52 11 U.S. Code §327(a).
53 Fed. R. Bankr. P. 2014(a), 2016(b).
54 Application to Employ Davis Polk at 3-4.
55 See, e.g., In re Southcross Energy Partners L.P., Case No. 19-10702 (MFW) (Bankr. D. Del. April 1, 2019); In re Windstream
Holdings, Inc., Case No. 19-22312 (RDD) (Bankr. S.D.N.Y. Feb. 25, 2019); In re Pernix Sleep, Inc., Case No. 19-10323
(CSS) (Bankr. D. Del. Feb. 18, 2019); In re FullBeauty Brands Holdings Corp., Case No. 19-22185 (RDD) (Bankr. S.D.N.Y.
Feb. 3, 2019); In re PG&E Corp., Case No. 19-30088 (DM) (Bankr. N.D. Cal. Jan. 29, 2019).
56 Application to Employ Davis Polk at 5.
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advice and documentation for transactions, taking necessary and appropriate actions to preserve the
Debtors estates, taking necessary and appropriate actions in connection with the chapter 11 plan and
performing any other legal services necessary in connection with the chapter 11 case.57
Davis Polk’s rates at the time of the petition were $1,295 to $1,645 per hour for partners,
$525 to $1,075 per hour for associates and $305 to $425 per hour for paraprofessionals.58 Davis Polk
also regularly charged clients for expenses including travel, lodging, photocopying, postage, vendor
charges, and delivery service.59 In the year before the petition date, Davis Polk received a staggering
$37,352,542.59 for legal work on a variety of matters for the Debtors, including restructuring,
litigation and corporate governance.60 Davis Polk was not a creditor of the Debtors at the time the
petition was filed, had no conflicts of interest, and was otherwise “disinterested” as required by
§§327(a) and 328(c).61 The court granted the Debtor’s application to retain Davis Polk as
restructuring counsel nunc pro tunc pursuant to the terms in the application despite the objection of
the U.S. trustee based on the ground that the firm’s request to hold an evergreen retainer of
$5,115,859.35 throughout the duration of the case was impermissible.6263
Between September 15, 2019 and January 31, 2021 Davis Polk submitted 4 interim
applications for professional compensation requesting a total of $105,843,992.55 in compensation

Id. at 6-7.
Application to Employ Davis Polk, Exhibit A at 10.
59 Id.
60 Id. at 9.
61 Id.; 11 U.S. Code §§327(a) and 328(c).
62 Order Granting Debtors’ Application for Authority to Employ and Retain Davis Polk & Wardwell LLP as Attorneys
for the Debtors Nunc Pro Tunc to the Petition Date .pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y.
filed Sept. 15, 2019), https://perma.cc/CEL2-J9YK.
63 Objection of The United States Trustee to Entry of Orders Approving the Retentions of (1) Davis Polk & Wardwell,
LLP, (2) Skadden Arps Slate Meagher & Flom, LLP and (3) Wilmer Cutler Pickering Hale and Dore LLP .pdf, In re
Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), https://perma.cc/76E5-UHVV; see also
Debtors’ Reply to the Objection of United States Trustee to Debtors’ Application for an Order Authorizing
Employment and Retention of Davis Polk & Wardwell LLP, Skadden, Arps, Slate, Meagher & Flom LLP and Wilmer
Cutler Pickering Hale And Dorr LLP As Attorneys For The Debtors Nunc Pro Tunc To The Petition Date .pdf, In re
Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), https://perma.cc/9VZK-G868.
57
58
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and reimbursement of $759,739.83 in expenses.64 Davis Polk professionals billed a total of 82,022.02
hours across a variety of practice areas including restructuring, litigation, corporate, intellectual
property, executive compensation and benefits, and tax in order to provide “necessary services” to
the Debtors.65 The court awarded the full compensation and expenses requested in the first three
applications and no order had been entered for the fourth at the time of this writing, but past
conduct indicates that the fourth application will be granted.66 Just like one man’s trash can be
another man’s treasure, Purdue’s bankruptcy is Davis Polk’s fortune.

64 First Interim Application of Davis Polk & Wardwell LLP for Compensation for Services Rendered and
Reimbursement of Expenses Incurred as Counsel to the Debtors and Debtors in Possession for the Period from
September 15, 2019 Through January 31, 2020 Cover Sheet.pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy
S.D.N.Y. filed Sept. 15, 2019), [hereinafter “First Application of Davis Polk for Compensation],
https://perma.cc/96QQ-ZSYA; Second Interim Application of Davis Polk & Wardwell LLP for Compensation for
Services Rendered and Reimbursement of Expenses Incurred as Counsel to the Debtors and Debtors in Possession for
the Period from September 15, 2019 Through January 31, 2020 Cover Sheet.pdf, In re Purdue Pharma L.P., No. 19-23649
(Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Second Application of Davis Polk for Compensation],
https://perma.cc/SGN7-74W8; Third Interim Application of Davis Polk & Wardwell LLP for Compensation for
Services Rendered and Reimbursement of Expenses Incurred as Counsel to the Debtors and Debtors in Possession for
the Period From June 1, 2020 through September 30, 2020 Cover Sheet.pdf, In re Purdue Pharma L.P., No. 19-23649
(Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Third Application of Davis Polk for Compensation],
https://perma.cc/96W9-2QG2; Fourth Interim Application of Davis Polk & Wardwell LLP for Compensation for
Services Rendered and Reimbursement of Expenses Incurred as Counsel to the Debtors and Debtors in Possession for
the Period from September 15, 2019 Through January 31, 2020 Cover Sheet.pdf, In re Purdue Pharma L.P., No. 19-23649
(Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Fourth Application of Davis Polk for Compensation],
https://perma.cc/YA2S-KR3P.
65 First Application of Davis Polk for Compensation at 5; Second Application of Davis Polk for Compensation at 5;
Third Application of Davis Polk for Compensation at 5; Fourth Application of Davis Polk at 5.
66 Omnibus Order Granting First Interim Fee Applications of Professionals for Allowance and Payment of
Compensation for Professional Services Rendered and for Reimbursement of Actual and Necessary Expenses .pdf, In re
Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Omnibus Order Granting
First Interim Fee Applications”], https://perma.cc/6MVJ-R7TR; Omnibus Order Granting Second Interim Fee
Applications of Professionals for Allowance and Payment of Compensation for Professional Services Rendered and for
Reimbursement of Actual and Necessary Expenses .pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y.
filed Sept. 15, 2019), [hereinafter “Omnibus Order Granting Second Interim Fee Applications”],
https://perma.cc/T6SG-7JZ5; Omnibus Order Granting Third Interim Fee Applications of Professionals for Allowance
and Payment of Compensation for Professional Services Rendered and for Reimbursement of Actual and Necessary
Expenses .pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter Omnibus
Order Granting Third Interim Fee Applications], https://perma.cc/AJ9G-2SNN.
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AlixPartners
The Debtors applied to retain AlixPartners, LLP as its primary financial advisors nunc pro tunc
to the petition date.67 Section 327(a) also allows the DIP to employ non legal professionals with the
court’s approval.68 As with attorneys, rule 2014(a) requires the DIP to file an application to the court
to employ professionals and rule 2016(b) requires disclosure of the fees promised or paid to the
professionals.69 The Debtors sought to employ AlixPartners to provide necessary financial advisory
services in connection with the debtors chapter 11 cases because of its “wealth of experience”,
reputation, and previous work in large complex chapter 11 cases.70 Similar to the Debtors’
arguments for employing Davis Polk, the Debtors argued that AlixPartners should be retained
because acquired significant knowledge of the Debtors, their financial affairs, debt structure,
operations and other matters through their pre-petition work, which in turn would preserve the
resources of the bankruptcy estate since AlixPartners was already up to speed.71 The Debtors
asserted that AlixPartners’s financial services were necessary, would not be duplicated by any other
professionals retained and that it was disinterested.72 AlixPartners hourly rates at the time of the
application ranged from $285 per hour for paraprofessionals to $1,165 per hour for a managing
director.73 The Debtors also provided that AlixPartners would be reimbursed for reasonable and
necessary expenses including transportation costs, lodgings, and meals.74 As part of their

67 Debtors’ Application for an Order Authorizing the Debtors to Retain and Employ AlixPartners, LLP
as Financial Advisor Nunc Pro Tunc to the Petition Date .pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy
S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Application to Employ AlixPartners”], https://perma.cc/SV6R-EF45.
68 11 U.S. Code §327(a).
69 Fed. R. Bankr. P. 2014(a), 2016(b).
70 Application to Employ AlixPartners at 4. Alix Partners recent chapter 11 experience includes advising on the
following cases: In re Fullbeauty Brands Holdings Corp., Case No. 19-22185 (RDD) (Bankr. S.D.N.Y. March 8, 2019); In re
Ditech Holding Corporation, Case No. 19-10412 (JLG) (Bankr. S.D.N.Y. March 25, 2019); In re Pacific Drilling S.A., Case No.
17-13193 (MEW) (Bankr. S.D.N.Y. Dec. 14, 2017); In re CGG Holdings (U.S.) Inc., Case No. 17-11637 (MG) (Bankr.
S.D.N.Y. July 14, 2017).
71 Application to Employ AlixPartners at 7.
72 Id.
73 Id. at 8.
74 Id.
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compensation, the Debtors also agreed to indemnify AlixPartners and its affiliates and employees
from any claims, liabilities, losses etc. that arise from the engagement of AlixPartners in the chapter
11 case, only excluding losses caused by gross negligence, bad faith, or willful conduct.75
The application was granted but the court modified the indemnity provisions to require that
AlixPartners’s requests for payment of indemnification must be made to the bankruptcy court and
would be subject to the court’s review.76 AlixPartners was granted $20,399,334.38 in fees and
expenses between September 2019 and January 2021.77
Other professionals employed by the Debtors include PJT Partners LP (financial)
Cornerstone Research (litigation consulting), Arnold & Porter Kaye Scholer LLP (legal), King &
Spalding LLP (legal) KPMG LLP (jointly retained with the Official Committee of Unsecured
Creditors for accounting and consulting services) Jones Day (legal), Skadden, Arps, Slate, Meagher &
Flom LLP (legal), Dechert LLP (legal), Wilmer Cutler Pickering Hale and Dorr LLP (legal), and
Ernst & Young LLP (accounting).78

Official Committee of Unsecured Creditors
The Official Committee of Unsecured Creditors (the “OCC”) applied to retain Akin Gump
Strauss Hauer & Feld LLP (“Akin Gump”) as its lead counsel nunc pro tunc to 11 days after the
petition date.79 Section 328(a) allows appointed committees, such as the OCC, to employ

Id. at 10.
Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as Financial Advisor Nunc Pro Tunc to the
Petition Date .pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019),
https://perma.cc/A3F7-57AH.
77 Omnibus Order Granting First Interim Fee Applications, Omnibus Order Granting Second Interim Fee Applications,
Omnibus Order Granting Third Interim Fee Applications.
78 Omnibus Order Granting Third Interim Fee Applications.
79 Application of the Official Committee of Unsecured Creditors of Purdue Pharma L.P., Et. Al. to Retain and Employ
Akin Gump Strauss Hauer & Feld as Counsel Nunc Pro Tunc September 26 1.pdf, In re Purdue Pharma L.P., No. 19-23649
(Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “OCC Application to Employ Akin Gump”],
https://perma.cc/W9HY-SU9E.
75
76
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professionals on reasonable terms with court approval.80 Section 1103(a) specifically authorizes
members of an appointed committee, such as the OCC, to select and authorize the employment of
attorneys and other professionals at a regularly scheduled meeting with a majority of the committee
members present.81 Rule 2014(a) requires the OCC apply for an order authorizing the employment
of such professionals.82 The OCC, made up of Blue Cross and Blue Shield Association, CVS
Caremark Part D Services L.L.C. and Caremark PCS Health L.L.C, Cheryl Juaire, Kara Trainor, LTS
Lohman Therapy Systems Corporation, Pension Benefit Guaranty Corporation, Ryan Hamption,
Walter Lee Salmons, and West Boca Medical Center, selected Akin Gump to serve as lead counsel
on September 29, 2019.83
The OCC asserted that employment of Akin Gump was necessary to advise and represent
the committee throughout the chapter 11 case and that Akin Gump had extensive knowledge and
expertise representing unsecured creditors’ committees.84 Section 330 allows the court to award
compensation from a debtor’s estate to a professional employed under §1103.85 Section 503(b)
allows the professional fees to be treated as administrative expenses after notice and a hearing.86
Section 507(a)(2) provides that administrative expenses have priority over all unsecured claims

11 U.S. Code §328(a).
11 U.S. Code §1103(a).
82 Fed. R. Bankr. P. 2014(a).
83 OCUC Application to Employ Akin Gump at 6. The OCUC also selected Bayard, P.A. to serve as its “efficiency
counsel,” Province Inc. to serve as its financial advisor, and Jefferies Group LLC to serve as its investment banker on
September 29, 2019. Id.
84 Id. at 5. See In re Vanguard Natural Resources, LLC; In re Insys Therapeutics, Inc.; In re Pernix Sleep, Inc.; In re Sears Holdings
Corp; In re Nine West Holdings, Inc.; In re iHeartMedia, Inc.; In re Cumulus Media Inc.; In re EMAS Chiyoda Subsea, Ltd.; In re
Metals USA, Inc.; In re Emerald Oil, Inc.; In re Goodrich; Petroleum Corp.; In re SandRidge Energy Inc.; In re Quiksilver, Inc.; In re
Chassix Inc.; In re BPZ Resources, Inc; In re Cal Dive International, Inc.; In re Swift Energy Co.; In re Excel Maritime Carriers LTD;
In re Hawker Beechcraft, Inc.; In re Overseas Shipholding Group, Inc.; In re Edison Mission Energy, et al.; In re Dynegy Holdings, LLC;
In re R.E. Loans, LLC; In re Delta Petroleum Corp.; In re Vitro America, LLC; In re Friendly Ice Cream Corporation; In re Seahawk
Drilling, Inc.; In re Saint Vincent’s Catholic Medical Centers of New York; In re Chemtura Corp.; In re TOUSA, Inc.; In re Delta Air
Lines, Inc.; In re ATA Holdings Corp.
85 11 U.S. Code §330(a).
86 11 U.S. Code §503(a).
80
81
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except domestic support obligations owed by the debtor as of the date of the petition.87 The OCC
requested that all fees and costs be paid as administrative expenses of the Debtors’ estate pursuant
to these sections.88 The OCC listed the Akin Gump professionals who would primarily work on the
case along with their rates ranging from $1,550 per hour for the most expensive partner to $660 to
the cheapest associate on the case.89 The OCC further argued that nunc pro tunc employment was
appropriate under the circumstances because the committee needed counsel to work on important,
time sensitive matters prior to the submission and approval of the application.90
The court granted the application.91 In the time between September 26, 2019 and January 31,
2021 Akin Gump requested $67,197,542.50 in professional fees.92 Akin Gump agreed to a total
reduction of $259,324.25 to allay the fee examiner’s concerns through the first three applications.93
The fourth fee application has not been ruled on at the time of this writing.
Other professionals employed by the OCC in this case include Jefferies LLC (financial),
Kurtzman Carson Consultants LLC (legal), Province, LLC (financial), Bedell Cristin Jersey
Partnership (legal), and Cole Schotz P.C. (legal).94

11 U.S. Code §507(a)(2).
OCUC Application to Employ Akin Gump at 6.
89 Id. at 8.
90 Id. at 10.
91 Order Authorizing the Official Committee of Unsecured Creditors of Purdue Pharma L.P., Et Al. to Retain
and Employ Akin Gump Strauss Hauer & Feld Llp as Counsel, Nunc Pro Tunc to September 26, 2019, 1.pdf,
https://perma.cc/TDU3-ZC4B.
92 Omnibus Order Granting First Interim Fee Applications; Omnibus Order Granting Second Interim Fee Applications;
Omnibus Order Granting Third Interim Fee Applications; Summary Cover Sheet to the Fourth Interim Fee Application
of Akin Gump Strauss Hauer & Feld LLP As Counsel to the Official Committee of Unsecured Creditors of Purdue
Pharma L.P., Et Al., for Allowance of Compensation for Services Rendered
and Reimbursement of Expenses Incurred for the Period of October 1, 2020 Through and Including January 31, 2021,
.pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Fourth Interim Fee
Application of Akin Gump”], https://perma.cc/S3FC-YEPD.
93 Omnibus Order Granting First Interim Fee Applications; Omnibus Order Granting Second Interim Fee Applications;
Omnibus Order Granting Third Interim Fee Applications; Fourth Interim Fee Application of Akin Gump.
94 Third Omnibus Order Granting Interim Fee Applications.
87
88
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The Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants also
employed various professionals including Brown Rudnick LLP (legal), Otterbourg, P.C. FTI
Consulting (financial), Gilbert LLP (legal), Kramer Levin Naftalis & Frankel LLP (legal), Houlihan
Lokey Capital, Inc. (financial), and Bielli & Klauder (legal).95 Apparently it takes a village to
reorganize a company. It is important to keep in mind the role of professionals in a chapter 11
reorganization. Unsecured creditors likely see professionals, especially those employed by the debtor
as taking slices of the pie of the bankruptcy estate, resulting in lower recovery for the creditors. The
professionals would likely respond that their services enlarge the pie, creating more value for
everyone, and in reality, maximize creditor recovery. Like most polarizing issues, the truth is likely
somewhere in the middle. Focusing in on the massive professional fees generated in a chapter 11
reorganization is certainly an eye-opening experience for many people who are not familiar with
such proceedings.

95

Id.
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FIRST DAY MOTIONS
Filing of Chapter 11 Petition
On the Petition Date, the Debtors filed a number of first day motion and applications
seeking authorization to maintain their operations in the ordinary course (collectively, the “First Day
Motions”). Through these motions the Debtors sought to maintain their business operations and
minimize any post-petition interruptions.96

Joint Administration
First, the Debtors filed a motion for joint administration of Chapter 11 cases for it and it
twenty-three affiliates.97 Per Bank R. 1015(b) when “two or more petitions are pending in the same
court by or against . . . and debtor and an affiliate, the court may order joint administration of the
estates.”98 The Debtors argued that given the corporate relationship amongst the parties joint
administration is warranted to avoid duplicative notices, applications, and orders thereby saving the
court, stakeholders, claimants, and the Debtors considerable time, expense, and resources.99
No objections to this motion were filed and the court entered an order approving the relief
shortly after.100

96 Plan Disclosure Statement, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Mar. 15
2021), https://perma.cc/MY7W-UNVR.
97
Motion of Debtors for Entry of an Order Directing Joint Administration of Chapter 11 Cases, In re Purdue Pharma
L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 16, 2019), https://perma.cc/Q8G6-53FG.
98 Id. at 7.
99 Id. at 3-4.
100 Order Granting Motion Directing Joint Administration of Chapter 11 Cases, In re Purdue Pharma L.P. et al., Case
No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 18, 2019), https://perma.cc/CFF4-FD2E.

23

Claims and Noticing Agent
Purdue next filed an application to appoint Prime Clerk LLC as the claims and noticing
agent on its behalf.101 The Debtors sought Prime Clerk to assume full responsibility for the
distributions of notices and the maintenance, processing and docketing of proofs of claim filed in
the Debtors’ bankruptcy.102 In its motion, the Debtors attested that selecting Prime Clerk to act as
its claims and noticing agent satisfies the court’s protocol for the employment of claims and noticing
agents per 28 U.S.C. §156(c)103 and Prime Clerk’s rates are competitive.104
No objections to this motion were filed and the court granted the relief shortly after.105

Cash Management System
The Debtor sought permission from the court to continue to operate its cash management
system, fund the operation of its subsidiaries, maintain its existing bank accounts (including opening
new ones or closing existing ones), and maintain its business forms (e.g., letterhead, envelopes,
purchase orders, invoices, sales order acknowledgements, etc.).106 Through this the Debtors
primarily sought to continue to fund its operations.107

Application for an Order Appointing Prime Clerk LLC as Claims and Noticing Agent for the Debtors, In re Purdue
Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Nov. 17, 2019), https://perma.cc/A35D-9VSD.
102 Id. at 3.
103 28 U.S.C. § 156 https://perma.cc/XS93-TE46.
104 Id.
105 Order Granting Application Authorizing Retention and Appointment of Prime Clerk LLC as Claims and Noticing
Agent for the Debtors, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 18, 2019),
https://perma.cc/HGP9-C2MW.
106 Motion of Debtors for Entry of Interim and Final Orders Authorizing (I) Debtors to Continue to Use Existing Cash
Management Systems and Maintain Existing Bank Accounts and Business Forms and (II) Financial Institutions to
Honor and Process Related Checks and Transfers, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr.
S.D.N.Y. Sept. 16, 2019), https://perma.cc/YE7D-6XNM.
107 Id. at 3.
101
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No objections to this motion were filed and an interim order was entered shortly after.108 A
final order was entered on November 25, 2019.109

Prepetition Employee Benefits
Next Debtors filed a motion for authorization to (in their sole discretion) continue meeting
its pre-petition financial obligations to employees, retirees, and financial institutions.110 Chiefly, the
Debtors sought authorization to pay pre-petition employee obligations for its approximately seven
hundred employees.111 These obligations included payroll, withholdings, business expenses, benefits
including relocation and health and welfare, workers’ compensation, savings plans, pension plans,
and non-medical retirement obligations, severance, and bonuses.112 The Debtors feared that without
the ability to meet these prepetition obligations their key employees would abandon the company
rendering it less able to compete upon reorganization.113
An interim order granting the relief was entered on September 18, 2019.114 However,
objections to this motion were filed by the United States Trustee for Region 2,115 Nevada Counties

Interim Order Granting Motion Authorizing (I) Debtors to Continue to Use Existing Cash Management Systems and
Maintain Existing Bank Accounts and Business Forms and (II) Financial Institutions to Honor and Process Related
Checks and Transfers, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 18, 2019),
https://perma.cc/SJZ6-XERG.
109 Final Orders Granting Motion Authorizing (I) Debtors to Continue to Use Existing Cash Management Systems and
Maintain Existing Bank Accounts and Business Forms and (II) Financial Institutions to Honor and Process Related
Checks and Transfers, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Nov. 25, 2019),
https://perma.cc/2H3E-GT9P.
110 Motion of Debtors for Entry of an Order Authorizing (I) Debtors to (A) Pay Pre-Petition Wages, Salaries, Employee
Benefits and Other Compensation and (B) Maintain Employee Benefits Programs and Pay Related Administrative
Obligations, (II) Employees and Retirees to Proceed with Outstanding Workers' Compensation Claims and (III)
Financial Institutions to Honor and Process Related Checks and Transfers, In re Purdue Pharma L.P. et al., Case No.
19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 16, 2019), https://perma.cc/EKU3-KGTM.
111 Id.
112 Id. at 4-22.
113 Id. at 22.
114 Interim Order Granting Motion Authorizing (I) Debtors to (A) Pay Pre-Petition Wages, Salaries, Employee Benefits
and Other Compensation and (B) Maintain Employee Benefits Programs and Pay Related Administrative Obligations,
(II) Employees and Retirees to Proceed with Outstanding Workers' Compensation Claims and (III) Financial
Institutions to Honor and Process Related Checks and Transfers, In re Purdue Pharma L.P. et al., Case No. 19-23649
(RDD) (Bankr. S.D.N.Y. Sept. 18, 2019), https://perma.cc/N56L-KLRW.
115 United States Trustee Objection to Motion For Order Authorizing (I) Debtors to (A) Pay Pre-Petition Wages,
Salaries, Employee Benefits and Other Compensation and (B) Maintain Employee Benefits Programs and Pay Related
108
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and Municipalities,116 the Commonwealth of Pennsylvania,117 and the Ad Hoc Group of NonConsenting States,118 and the State of Arizona.119 The New York State Department of Financial
Services also submitted an informal objection.120 Chiefly, the objections focused on the $38,000,000
in bonus and severance payments the Debtors sought for various employees.121 The United States
Trustee argued that this type of payment is not typical of a first day wage motion which usually seek
only to stabilize and continue operations after filing bankruptcy.122
In a reply, the Debtors argued that the events prompting the bonus and severance payments
(the shuttering of a manufacturing facility in North Carolina) were set in motion prior to its filing for
bankruptcy and that these payments are a sound exercise of its business judgment.123
Following a hearing, the Debtors’ motion was granted.124

Administrative Obligations, (II) Employees and Retirees to Proceed with Outstanding Workers' Compensation Claims
and (III) Financial Institutions to Honor and Process Related Checks and Transfers, In re Purdue Pharma L.P. et al.,
Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 27, 2019), https://perma.cc/K6RP-USZE.
116 Statement Nevada Counties and Municipalities’ Joinder, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD)
(Bankr. S.D.N.Y. Oct. 2, 2019), https://perma.cc/H23Q-GJZD.
117 Commonwealth of Pennsylvania Objection to Motion and Joinder to United States Trustee’s Objection, In re Purdue
Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019), https://perma.cc/8LKH-BTG7.
118 Joinder/Objection by the Ad Hoc Group of Non-Consenting States, In re Purdue Pharma L.P. et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019), https://perma.cc/SEG7-TLWE.
119 Joinder/Objection by the State of Arizona, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr.
S.D.N.Y. Oct. 3, 2019), https://perma.cc/KY54-4RME.
120 Letter, Filed on Behalf of New York State Department of Financial Services, In re Purdue Pharma L.P. et al., Case
No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 23, 2019), https://perma.cc/82NK-XP8A.
121 Supra note 33, at 1-3.
122 Id.
123 Debtors’ Omnibus Reply in Support of Motion of Debtors for Entry of an Order Authorizing (I) Debtors to (A) Pay
Pre-Petition Wages, Salaries, Employee Benefits and Other Compensation and (B) Maintain Employee Benefits
Programs and Pay Related Administrative Obligations, (II) Employees and Retirees to Proceed with Outstanding
Workers' Compensation Claims and (III) Financial Institutions to Honor and Process Related Checks and Transfers, In
re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 8, 2019), https://perma.cc/TCT6H9SN.
124 Final Order Authorizing (I) Debtors to (A) Pay Pre-Petition Wages, Salaries, Employee Benefits and Other
Compensation and (B) Maintain Employee Benefits Programs and Pay Related Administrative Obligations, (II)
Employees and Retirees to Proceed with Outstanding Workers' Compensation Claims and (III) Financial Institutions to
Honor and Process Related Checks and Transfers, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr.
S.D.N.Y. Oct. 16, 2019), https://perma.cc/H6WC-YAZ2.
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Utility Services
On September 16, 2019, the Debtors filed a motion seeking the court to prohibit its utilities
from altering, refusing, or discontinuing services, to declare its utility providers are adequately
assured of future performance, and to establish procedures for determining requests for additional
adequate assurance.125 Chiefly, Purdue was concerned that its utility providers would alter, refuse, or
discontinue service due to prepetition amounts owed or fear of inability to pay.126
An order granting the relief requested was entered on October 16, 2019.127

Governmental Authorities
Purdue sought an order authorizing the payment of certain taxes and business licenses,
compliance and regulatory fees to various federal, state, county and city (collectively referred to as
Governmental Authorities), both pre- and post-petition.128 The Debtors stated that in the ordinary
course of business, they collect, withhold, and incur various taxes and fees. The Debtors claimed
that they believe that many of the taxes and fees they collected prepetition are not property of the
estate and they are holding these taxes and fees in trust for the applicable government entities.129
The Debtors were seeking to pay these certain taxes to avoid any government interruptions of its

125 Motion of Debtors for Entry of Interim and Final Orders (I) Prohibiting Utilities From Altering, Refusing or
Discontinuing Service, (II) Deeming Utilities Adequately Assured of Future Performance and (III) Establishing
Procedures for Determining Requests for Additional Adequate Assurance, Purdue Pharma L.P. et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Sept. 16, 2019), https://perma.cc/B8L3-ECY4.
126 Id. at 3-4.
127 Final Order (I) Prohibiting Utilities From Altering, Refusing or Discontinuing Service, (II) Deeming Utilities
Adequately Assured of Future Performance and (III) Establishing Procedures for Determining Requests for Additional
Adequate Assurance, Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 16, 2019),
https://perma.cc/F6BP-2TRU.
128
Motion of Debtors for Entry of Interim and Final Orders Authorizing (I) Debtors to Pay Certain Prepetition Taxes,
Governmental Assessments and Fees and (II) Financial Institutions to Honor and Process Related Checks and Transfers, Purdue
Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Nov. 17, 2019), https://perma.cc/ZW3Y-469D.
129 Id. at 4.
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reorganization. The Debtors also emphasized that the taxes and fees owed were entitled to priority
status per § 507(a)(8).130
An order granting this relief was entered on October 16, 2019.131

Critical Vendors
Purdue sought permission to pay all or a portion of their prepetition obligations accrued to
critical vendors twenty (20) days prior to its petition; without this ability, Purdue feared its critical
vendors would cease supply of goods and services essential to Debtor’s viability post-petition.132
Purdue requested up to $7.7 million be earmarked for such critical vendors.133 These vendors
include parties along its supply chain,134 clinic trial vendors,135 security and waste management
services,136 and foreign vendors.137 Purdue sought the ability to condition its continued payments to
the above vendors on an agreement that these vendors continue to supply gods or services for a
term agreeable to the Debtor.138

Id. at 12; see also 11 U.S.C. § 507(a)(8) https://perma.cc/J3LE-5M7Y.
Final Order Authorizing (I) Debtors to Pay Certain Prepetition Taxes, Governmental Assessments and Fees and (II)
Financial Institutions to Honor and Process Related Checks and Transfers, Purdue Pharma L.P. et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Oct. 16, 2019), https://perma.cc/H874-Q9PX.
132
Motion of Debtors for Entry of Interim and Final Orders Authorizing (I) Payment of Certain Pre-petition Claims of Critical
Vendors and (II) Financial Institutions to Honor and Process Related Checks and Transfers, 1-3, Purdue Pharma L.P. et al., Case
No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 16, 2019), https://perma.cc/34QN-TXWU.
133 Id. at 4.
134 Id. at 5 (these vendors provide ingredients and equipment components, storage and distribution services, equipment
servicing, batch release testing, monitoring, and manufacturing and packaging for its pharmaceutical products).
135 Id. at 7 (these vendors conduct clinic trials to ensure compliance with FDA regulations governing labeling, packaging,
storage, advertising, promotion, recordkeeping, and submission of safety data and other post-marketing data for the
products).
136 Id. at 8 (these vendors prevent theft, misuse, or unintended exposure to the Debtor’s pharmaceutical products for
their warehouses and transport vehicles).
137 Id. at 8-9 (Here, Debtor was concerned that foreign vendors may consider themselves beyond the reach of the court’s
jurisdiction and cease doing business, disregard the automatic stay, or file actions in foreign jurisdictions).
138 Id. 10-11.
130
131
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No objections to this motion were filed and an order authorizing this relief was entered
shortly after.139

Insurance Policies
Under § 363(c)(1),140 the Debtors sought an entry of an order authorizing them to maintain
or purchase insurance policies in accordance with their prepetition practices and procedures.141
Purdue’s insurance policies include liability, casualty, property, and other programs they deemed
necessary through the course of ordinary business.142 The Debtors also sought permission to
employ Marsha USA, and its affiliates, as an insurance broker.143 The broker would receive a
commission from the insurance premiums paid by the Debtors.144 The Debtors’ current aggregate
insurance premiums, under all its insurance policies, totaled approximately $3,200,000.145
No objections to the motion were filed and an order granting the relief requested was
entered on October 16, 2019.146

139 Final Order Authorizing (I) Payment of Certain Pre-petition Claims of Critical Vendors and (II) Financial Institutions
to Honor and Process Related Checks and Transfers, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD)
(Bankr. S.D.N.Y. Oct. 16, 2019), https://perma.cc/5CA6-8SW5.
140 11 U.S.C. § 363(c)(1) https://perma.cc/2NG2-93YF.
141 Motion of Debtors for Entry of Interim and Final Orders Authorizing (I) the Debtors to Continue and Renew Their
Liability, Property, Casualty and Other Insurance Policies and Honor all Obligations in Respect Thereof and (II)
Financial Institutions to Honor and Process Related Checks and Transfers, In re Purdue Pharma L.P. et al., Case No.
19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 16, 2019), https://perma.cc/25HS-GACC.
142 Id. at 4.
143 Id.
144 Id. at 5.
145 Id.
146 Final Order Authorizing (I) the Debtors to Continue and Renew Their Liability, Property, Casualty and Other
Insurance Policies and Honor all Obligations in Respect Thereof and (II) Financial Institutions to Honor and Process
Related Checks and Transfers, In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 16,
2019), https://perma.cc/G3UP-K89W.
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Prepetition Obligations to Customers
Purdue filed a motion seeking an order to allow (but not require) them to honor certain
prepetition obligations owed to customers under existing customer programs (the “Customer
Programs”) and third-party service agreements (the “Third Party Service Agreements”).147
The Customer Programs, per the Debtors, were integral to the sale of its product and to
ensure continuity of product supply to patients.148 This program includes its wholesalers which are
its primary sales channel of its prescription products to retail drug stores, mass merchandisers,
pharmacies, hospitals long-term care and other mail, retail and non-retail institutions.149 It also
included government programs, such as Medicaid150 and Tricare.151
The Third-Party Service Agreements included third party service agreements where Debtor,
Avrio Health L.P. (subsidiary) via Emerson Health LLC takes orders, issues invoices, collects cash,
issues credit, and distributes non-prescription consumer health products.152 Following, Emerson
sells the product to retailers and wholesalers, who then sell the product to retail drug stores, mass
merchandisers, pharmacies, hospitals, long-term care and other mail, retail and non-retail
institutions.153
No objections to the motions were filed and an order granting the relief requested was
entered on October 16, 2019.154
147

Motion of Debtors for Entry of Interim and Final Orders Authorizing (I) Debtors to Honor Prepetition Obligations to
Customers and Related Third Parties and to Otherwise Continue Customer Programs (II) Relief from Stay to Permit Setoff in
Connection with the Customers and Programs and (III) Financial Institutions to Honor and Process Related Checks and
Transfers, Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 16, 2019), https://perma.cc/W6SQDABF.
148 Id. at4.
149 Id.
150 Id. at 9 (“Medicaid is a health program, jointly funded by state and federal governments and managed by the states,
that assist low-income individuals and families in obtaining healthcare.”).
151 Id. at 13 (“Tricare is a federal program administered by the Defense Health Agency of the Department of Defense,
which coves prescription products at pharmacies for military beneficiaries and their dependents.”).
152 Id. at 14.
153 Id.
154 Final Order Authorizing (I) Debtors to Honor Prepetition Obligations to Customers and Related Third Parties and to
Otherwise Continue Customer Programs (II) Relief from Stay to Permit Setoff in Connection with the Customers and
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Surety Bond Program
The Debtors moved to maintain, continue and renew, their surety bond program in their
discretion in accordance with the same practices and procedures that were in effect before the
petition date.155 The Debtors’ surety bond program consisted of providing surety bonds to third
parties to secure the Debtors’ payment or performance of obligations required by law, including
obligations to state agencies to maintain licenses to sell or distribute pharmaceutical products.156 The
Debtors’ surety bonds included indemnity agreements whereby the Debtors agreed to indemnify the
issuers from any loss, damage, cost, or expense they may incur by reason of their execution of bonds
on behalf of the debtors.157 By their motion, the Debtors sought authorization to pay all amounts
under the surety bond program due and payable after the petition date, to renew or obtain new
surety bonds as needed in the ordinary course of business and to honor the indemnity agreements
between the Debtors and the surety bond issuers.158 The amounts of these surety bonds ranged from
$5,000 to $100,000 for a total of $896,508.61.159
The Debtors asserted that they had the authority under § 363(c)(1) as Debtors in Possession
(“DIP”) to pay all post-petition amounts due under the surety bond program and renew or obtain
new surety bonds. 160 § 363(c)(1) provides that “the trustee may enter into transactions, including the
sale or lease of property of the estate, in the ordinary course of business, without notice or a hearing,

Programs and (III) Financial Institutions to Honor and Process Related Checks and Transfers, Purdue Pharma L.P. et
al., 1-3, Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 16, 2019), https://perma.cc/9NLJ-9E6H.
155 Motion of Debtors for Entry of Interim and Final Orders Authorizing the Debtors to Continue and Renew Surety
Bond Program 3.pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter
“Motion to Continue and Renew Surety Bond Program”], https://perma.cc/MQ4M-DR3V.
156 Motion to Continue and Renew Surety Bond Program at 3-4.
157 Id. at 4-5.
158 Id. Program at 3.
159 Id., Exhibit C.
160 Id. at 6.
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and may use property of the estate in the ordinary course of business without notice or a hearing.”161
The Debtors argued that maintenance of their surety bond program was within the ordinary course
of the Debtors’ business since surety bonds were required for the Debtors to continue selling and
distributing pharmaceutical products.162
Furthermore the Debtors argued that § 364(c) permitted them to renew, replace, or enter
into new surety bond facilities to the extent that is considered secured credit.163 § 364(c) provides
that “if the trustee is unable to obtain unsecured credit . . . as an administrative expense, the court,
after notice and a hearing, may authorize the obtaining of credit or the incurring of debt— (1) with
priority over any or all administrative expenses . . . (2) secured by a lien on property of the estate that
is not otherwise subject to a lien; or (3) secured by a junior lien on property of the estate that is
subject to a lien.”164 The Debtors argued that due to their current financial status it was unlikely the
debtors would be able to renew or replace their surety bonds on an unsecured basis and therefore
continuing the Debtors’ business operations throughout the reorganization process required a
secured extension of credit to the extent that renewal, replacement or entry into a new surety bond
is deemed a secured extension of credit.165
The Debtors were careful to include language asking the court not to consider the
continuation of the surety bond program as requested to constitute assumption of any executory
contracts.166 Section 365 of the bankruptcy code provides that the DIP may assume or reject any
unexpired executory contract of the debtor.167 The Debtors were essentially seeking to continue their

11 U.S. Code § 363.
Motion to Continue and Renew Surety Bond Program at 6.
163 Id.
164 11 U.S. Code § 364(c).
165 Motion to Continue and Renew Surety Bond Program at 6.
166 Id. at 6-7.
167 11 U.S. Code § 365.
161
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prepetition surety bond program and receive the associated benefits such as maintaining their state
licenses without binding themselves to the contracts and retaining the right to later reject the surety
bond contracts. Although it seems like the Debtors were asking to “have their cake and eat it too,”
no creditors objected to this arrangement. This is likely because the court and most of the creditors
agreed with the Debtors’ argument that maintaining the Debtors’ state licenses was necessary to
maximize the value of the bankruptcy estate and in turn provide maximum recovery to creditors.
Bankruptcy rule 6003(b) provides that the court shall not issue an order granting a motion
“to incur an obligation regarding property of the estate, including a motion to pay all or part of a
claim that arose before the filing of the petition” within 21 days after the filing of the petition unless
the relief is necessary to prevent immediate and irreparable harm.168 The Debtors argued that failure
to grant relief would result in immediate and irreparable harm because failure to make payment of
obligations under the surety bond program could result in the termination of their surety bonds or
issuers refusal to renew their surety bonds which could trigger cancelation of the Debtor’s licenses
to sell or distribute pharmaceutical products and jeopardize the Debtors’ ability to conduct their
operations to the detriment of all parties in interest.169
Bankruptcy rule 6004(h) provides that “an order authorizing the use, sale, or lease of
property other than cash collateral is stayed until the expiration of 14 days after entry of the order,
unless the court orders otherwise.”170 6004(a) requires notice of a proposed use sale or lease of
property outside of the ordinary course of business.171 The Debtors argued that the motion should

Fed. R. of Bankr. P. 6003.
Motion to Continue and Renew Surety Bond Program at 5. It is interesting that the Debtors are essentially arguing
that their ability to continue to manufacture and distribute pharmaceuticals is in the interest of parties who are suing the
Debtors for the disastrous results of their sale and manufacture of pharmaceuticals.
170 Fed. R. of Bankr. P. 6003.
171 Fed. R. of Bankr. P. 6004.
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be considered notice under 6004(a) and the 6004(h) stay should be waived because the relief
requested was necessary to avoid immediate and irreparable harm, to the extent that those
provisions applied.172
After an interim hearing the court entered an interim order granting the Debtors’ motion
before holding a final hearing and entering a final order granting the Debtors’ motion.173

Time to File Schedules and Statements of Financial Affairs
§521(a)(1) and bankruptcy rule 1007(b)(1) require a debtor to file (1) a schedule of assets and
liabilities, (2) a schedule of current income and expenditures, (3) a statement of the debtor’s financial
affairs and (4) a schedule of executory contracts and unexpired leases, among other documents.174
Bankruptcy rule 1007(c) provides that the required schedules and statements in a voluntary case
must be filed within 14 days of the petition.175 Bankruptcy rule 1007(c) further provides that an
extension of the to file schedules, statements and other required documents can only be granted on
motion for cause shown.176
The Debtors’ moved for a 30-day extension to the deadline for filing the schedules of assets
and statements under 1007(c).177 The Debtors’ argued that cause existed to extend the deadline
because (1) they had filed a list of creditors holding the three largest secured claims and 50 largest

Motion to Continue and Renew Surety Bond Program at 6.
Interim Order Authorizing Debtors to Continue and Renew Surety Bond Program .pdf, In re Purdue Pharma L.P., No.
19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), https://perma.cc/MSZ8-4973; Final Order Authorizing Debtors
to Continue and Renew Surety Bond Program .pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed
Sept. 15, 2019), https://perma.cc/YV69-RTL3.
174 11 U.S. Code §521; Fed. R. of Bankr. P. 1007.
175 Fed. R. of Bankr. P. 1007.
176 Fed. R. of Bankr. P. 1007.
177 Debtors’ Motion for an Order Extending the Time to File Schedules of Assets and Liabilities, Schedules of Current
Income and Expenditures, Schedules of Executory Contracts and Unexpired Leases and Statements of Financial Affairs
pdf.3, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Motion to Extend
Time to File Schedules and Statements of Financial Affairs”], https://perma.cc/A72V-URCU.
172
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unsecured claims on the Debtors’ consolidated estates178, (2) that accurate completion of the
required schedules and statements within the 14 day window due to the size and complexity of the
Debtors’ operations, the large amount of information required, and the onslaught of litigation,179 and
(3) because similar relief had been granted in other cases.180 The court entered an order granting the
Debtors’ a 30 day extension from the end of the initial 14 day period and allowing the debtors to
seek any further extensions by notice of presentment on five days’ notice.181

Authorization to Act in a Foreign Country
Bankruptcy code §1505 provides that an entity may be authorized by the court to act in a
foreign country in any way permitted by foreign law on behalf of the bankruptcy estate.182 In
addition to the Debtors’ extensive litigation in the United States, the Debtors were the subject of 10
class action lawsuits (with more proposed) in Canada at the time of the motion.183 Canadian law
allows a “foreign representative” authorized in a foreign proceeding to act as a representative on
behalf of a debtor company in foreign proceedings to commence ancillary proceedings in Canadian
courts.184
Although the Debtors stated that Purdue Pharma L.P. already had the ability to act as the
Debtors’ representative based on its powers as DIP, the Debtor’s moved for an order specifically

Id.
Id. at 3-5.
180 Id. at 5. The Debtors cited the following cases in support of their position: In re Windstream Holdings, Inc., No. 1922312 (RDD) (Bankr. S.D.N.Y. Feb. 28, 2019) (extending the time to file schedules by 30 days); In re Synergy
Pharmaceuticals Inc., Case No. 18-14010 (JLG) (Bankr. S.D.N.Y. Dec. 14, 2018) (extending the time to file schedules by 14
days); In re Sears Holdings Corp., Case No. 18- 23538 (RDD) (Bankr. S.D.N.Y. Oct. 16, 2018) (extending the time to file
schedules by 45 days); In re Tops Holding II Corp., Case No. 18-22279 (RDD) (Bankr. S.D.N.Y Feb. 26, 2018) (extending
the time to file schedules by 45 days); In re Pac. Drilling S.A., Case No. 17-13193.
181 Motion of Debtors for Entry of an Order (I) Authorizing Purdue Pharma L.P. to Act as Foreign Representative and
(II) Granting Related Relief 2.pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019),
https://perma.cc/3E6F-HVCR.
182 11 U.S. Code §1505.
183 Motion of Debtors for Entry of an Order (i) Authorizing Purdue Pharma L.P. to Act as Foreign Representative and
(ii) Granting Related Relief 3-5.pdf, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15,
2019),[hereinafter “Motion for Authorization to Act in a Foreign Country”], https://perma.cc/B6CD-87NU
184 R.S.C., 1985, c. C-36, 45(1) and 46.
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authorizing PPLP to act as the Debtors’ foreign representative for the purpose of commencing an
ancillary proceeding in Canada seeking to have the Debtors’ chapter 11 cases recognized by the
Canadian court.185 The Debtors argued that such an order was permitted under §1505, that such an
order would avoid any confusion under Canadian law whether Purdue Pharma L.P. was permitted to
act as the Debtor’s foreign representative, that courts had granted similar relief in other cases where
recognition of an ancillary proceeding in a foreign jurisdiction was sought,186 and that such an order
was appropriate and necessary because coordination of the Debtors’ chapter 11 case and the
Canadian lawsuits would maximize the value of the Debtors’ estates.
The court granted the order and stated that it “requests the aid and assistance of the
Canadian Court to recognize the Debtors’ chapter 11 cases as a ‘foreign main proceeding’ and PPLP
as a ‘foreign representative’ pursuant to the CCAA, and to recognize and give full force and effect in
all provinces and territories of Canada to th[e] Order.” The foreign representative subsequently
received a Canadian recognition order of the Debtors’ US chapter 11 proceedings.187 This initially
resulted in a temporary stay of any Canadian litigation against the Debtors.188 The Canadian courts’
recognition of the Debtors US chapter 11 case eventually led to the plaintiff Provinces filing a claim

Motion for Authorization to Act in a Foreign Country at 4-6.
See, e.g., In re Hollander Sleep Products, LLC, No. 19-11608 (MEW) (Bankr. S.D.N.Y. May 22, 2019); In re Aeropostale, Inc.,
No. 16-11275 (SHL) (Bankr. S.D.N.Y. May 6, 2016); In re Chemtura Corporation, No. 09-11233 (REG) (Bankr. S.D.N.Y.
Aug. 9, 2010); In re Payless Holdings LLC, No. 17-42267 (KAS) (Bankr. E.D. Mo. Apr. 5, 2017); In re CJ Holding Co., No.
16- 33590 (DRJ) (Bankr. S.D. Tex. July 21, 2016); In re Ultra Petroleum Corp., No. 16-32202 (MI) (Bankr. S.D. Tex. May 3,
2016).
187 Foreign Recognition Order, Insolvency Insider, (September 19, 2019) https://insolvencyinsider.ca/filingtype/foreign-recognition-order/, https://perma.cc/HGS7-5LN9.
188 Dylan Yan, Litigation and the Opioid Crisis: Purdue’s US Settlement in the Canadian Legal Context, MCGILL JOURNAL OF LAW
AND HEALTH, (December 13, 2020) https://mjlh.mcgill.ca/2020/12/13/litigation-and-the-opioid-crisis-purdues-ussettlement-in-the-canadian-legal-context/, https://perma.cc/ZC57-LV56.
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for over $67 billion against the Debtors in the US chapter 11 case, submitting their claims to be
adjudicated and administered in the U.S. proceedings.189

Waiving the requirement to file a list of creditors
Section 521(a)(1) of the bankruptcy code requires debtors to file a list of creditors.190
Bankruptcy rule 1007(a)(1) further requires debtors who voluntarily file for bankruptcy to file a list
containing the name and address of each creditor along with the debtor’s petition.191 The Debtors
argued that the requirement for the list of creditors should be waived because the debtors would be
filing a schedule of assets and liabilities (for which an extension was requested in a separate
motion)192 that would contain an extensive list of creditors and that filing a separate list of creditors
for each entity would be excessive.193 The Debtors asserted that the relief requested was within the
court’s equitable powers under §105 and provided citations to cases where similar relief was
granted.194 The court entered an order granting the Debtors motion provided that the waiver of the
requirement file with the petitions a list containing the name and address of certain creditors,
counterparties to executory contracts and unexpired leases and co-debtors “does not affect the

Anne Bucher, Oxycontin Maker Sued by Provinces Over Opioid Crisis, Top Class Actions, (November 16, 2020)
https://ca.topclassactions.com/lawsuit-settlements/lawsuit-news/oxycontin-maker-sued-by-provinces-over-opioidcrisis/, https://perma.cc/AY27-ZHYR.
190 11 U.S. Code §521(a)(1)
191 Fed. R. Bankr. P. 1007.
192 Motion to Extend Time to File Schedules and Statements of Financial Affairs.
193 Debtor’s Motion for an Order Waiving the Requirement to File List of Creditors at 4-5.
194Id. at 4-5; See In re Windstream Holdings, Inc., No. 19-22312 (RDD) (Bankr. S.D.N.Y. Mar. 5, 2019) (authorizing the
debtors to maintain a single, consolidated list of creditors in electronic format); In re Sears Holdings Corp., No. 18-23538
(RDD) (Bankr. S.D.N.Y. Oct. 16, 2018) (same); In re Republic Airways Holdings Inc., No. 16-10429 (SHL) (Bankr. S.D.N.Y.
Feb. 29, 2016) (same); In re NII Holdings, Inc., No. 14-12611 (SCC) (Bankr. S.D.N.Y. Sept. 16, 2014) (same); In re AMR
Corp., No. 11-15463 (SHL) (Bankr. S.D.N.Y. Nov. 30, 2011) (same).
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Debtors’ obligations to file schedules of executory contracts and unexpired leases and co-debtors
pursuant to section 521 of the Bankruptcy Code or Bankruptcy Rule 1007.”195

Suppression of Personally Identifiable Information
Section 107(c)(1)(A) allows the court to protect disclosure of information that would “create
an undue risk of identity theft or other unlawful injury.”196 The Debtors argued that individual
information should be suppressed because individuals may file claims containing medical or other
sensitive information protected by HIPAA, that disclosing names and residential addresses of
employees and individuals would pose an undue risk to the individuals privacy and personal safety
and create an undue risk of identity theft and that disclosing personal information about their
employees could hinder the Debtors’ efforts to attract and retain the employees necessary to
preserve the value of the Debtors’ estates for the benefit of creditors and other parties in interest.197
The Debtors asserted that the claims and noticing agent would serve these individuals at their home
addresses, ensuring that each individual will receive the same notices as other creditors without the
unnecessary public disclosure of the names and home address of such individuals.198 The Debtors
further asserted that similar relief had been granted by the court in similar circumstances.199The
motion was granted.200

195 Amended Order (i) Waiving Requirement to File List of Creditors, (ii) Authorizing the Debtors and the Claims and
Noticing Agent to Suppress Personally Identifiable Information for Individuals, (iii) Authorizing the Debtors’ Claims
and Noticing Agent to Withhold Publication of Claims Filed by Individuals Until Further Order of the Court and (iv)
Establishing Procedures for Notifying Creditors of the Commencement of the Debtors’ Chapter 11 Cases,
https://perma.cc/4R2P-272D.
196 11 U.S. Code §107(c)(1)(A).
197 Debtor’s Motion for an Order Waiving the Requirement to File List of Creditors at 6-7.
198 Id. at 8.
199 See, e.g., In re Windstream Holdings, Inc., No. 19-22312 (RDD) (Bankr. S.D.N.Y. Mar. 5, 2019); In re FULLBEAUTY
Brands Holdings Corp., No. 19-22185 (RDD)(Bankr. S.D.N.Y. Feb. 7, 2019); In re Nine West Holdings, Inc., No. 18-10947
(SCC) (Bankr. S.D.N.Y. Apr. 9, 2018); In re Cenveo Inc., No. 18-22178 (RDD) (Bankr. S.D.N.Y.) Feb. 6, 2018); In re
Promise Healthcare Group, LLC, Case No. 18-12491 (CSS) (Bankr. D. Del. Dec. 4, 2018); In re L.K. Bennett U.S.A., Inc.,
Case No. 19-10760 (KG) (Bankr. D. Del. Apr. 9, 2019).
200 Amended Order (i) Waiving Requirement to File List of Creditors, (ii) Authorizing the Debtors and the Claims and
Noticing Agent to Suppress Personally Identifiable Information for Individuals, (iii) Authorizing the Debtors’ Claims
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Withhold Publication of Claims Filed by Individuals Until Entry of the Bar Date Order or
Other Order of the Court
As previously discussed, §107(c)(1)(A) allows the court to protect disclosure of personally
identifiable information.201 Local rules for the Southern District of New York require the claims and
noticing agent to provide public access to the claims registers, including proofs of claims with
attachments.202 The Debtors moved for permission for the claims register agent to withhold
publication of claims filed by individuals until a Bar Date Order was entered to approve an
individual claim form and procedures to precent the disclosure of sensitive information. The
Debtors argued that failure to grant the motion would result in the claims and noticing agent being
required to publish proofs of claims filed by individuals that would contain personally identifiable
information as well as personal health information protected by HIPAA and that not publicizing
these details would provide minimal prejudice to any parties.203 The motion was granted.204

Proposed Procedures for Service of Notice of Commencement
Bankruptcy Rule 2002 requires the court clerk or a person directed by the court to provide
notice of an order for relief and of the date of the meeting of creditors to all creditors (among other
parties) by mail.205 Rule 2002(l) allows the court to “order notice by publication if it finds that notice
by mail is impracticable or that it is desirable to supplement the notice.206 The Debtors sought to

and Noticing Agent to Withhold Publication of Claims Filed by Individuals Until Further Order of the Court and (iv)
Establishing Procedures for Notifying Creditors of the Commencement of the Debtors’ Chapter 11 Cases.
201 11 U.S. Code §107(c)(1)(A)
202 Local Rule 5075-1.
203 Debtor’s Motion for an Order Waiving the Requirement to File List of Creditors at 10-11.
204 Amended Order (i) Waiving Requirement to File List of Creditors, (ii) Authorizing the Debtors and the Claims and
Noticing Agent to Suppress Personally Identifiable Information for Individuals, (iii) Authorizing the Debtors’ Claims
and Noticing Agent to Withhold Publication of Claims Filed by Individuals Until Further Order of the Court and (iv)
Establishing Procedures for Notifying Creditors of the Commencement of the Debtors’ Chapter 11 Cases.
205 See Fed. R. Bankr. P. 2002(a) and 2002(f).
206 Fed. R. Bankr. P. 2002(l).
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have the claims and noticing agent to undertake those mailings to creditors.207 The Debtors also
proposed publishing notice of commencement in to creditors in the wall street journal and the
national edition of the New York Times and/or USA today and on the website to be established by
the claims and noticing agent.208 The Debtors argued that publication of the notice would be a
practical way to notify creditors that miss the notice by mail and an efficient use of estate
resources.209 The Debtors asserted that this relief was within the court’s equitable powers under rule
105(a).210 The motion was granted.211

Motion to Establish Certain Notice, Case Management and Administrative Procedures
The Debtors moved for authorization to “(a) establish requirements for the filing and
service of notices, motions, applications, documents filed in support thereof and objections and
responses thereto, delineate standards for notices of hearing and hearing agendas, (c) articulate
mandatory guidelines for the scheduling of hearings and objection deadlines, (d) limit matters that
are required to be heard by the Court and (e) authorize the Debtors to (i) schedule, in cooperation
with the Court, periodic omnibus hearing dates and (ii) serve documents by email on certain parties
in interest.”212 The Debtors argued that the requested relief (collectively the “case management
procedures”) would benefit the court and all parties in interest by providing for omnibus hearings
for the Court to consider “a. motions, pleadings, applications, objections and responses thereto; b.
ensuring prompt and appropriate notice of matters affecting parties’ interests; c. allowing for

Debtor’s Motion for an Order Waiving the Requirement to File List of Creditors at 11.
Id.
209 Id. at 12.
210 Id.
211 Amended Order (i) Waiving Requirement to File List of Creditors, (ii) Authorizing the Debtors and the Claims and
Noticing Agent to Suppress Personally Identifiable Information for Individuals, (iii) Authorizing the Debtors’ Claims
and Noticing Agent to Withhold Publication of Claims Filed by Individuals Until Further Order of the Court and (iv)
Establishing Procedures for Notifying Creditors of the Commencement of the Debtors’ Chapter 11 Cases.
212 Motion of Debtors for Entry of an Order Establishing Certain Notice, Case Management, and Administrative
Procedures pdf. 3, In re Purdue Pharma L.P., No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019) [hereinafter
“Motion to Establish Case Management Procedures”], https://perma.cc/TG78-2DN6.
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electronic notice pursuant to the Court’s electronic filing system; d. providing ample opportunity to
parties in interest to prepare for and respond to matters before the Court; e. reducing the substantial
administrative and financial burden that would otherwise be placed on the Debtors and other parties
in interest who file documents in these chapter 11 cases; and f. reducing the administrative burdens
on the Court and the clerk of the Court.”213
The Debtors asserted that the court had the power to grant this motion under §105 of the
bankruptcy code which gives bankruptcy courts broad equitable powers to “issue any order, process,
or judgment that is necessary or appropriate” to carry out the provisions of the bankruptcy code.214
Additionally, the Debtors stated that the court had the authority to grant the motion under
bankruptcy rules 2002(m), 9007, 9036 and 1015(c).215 These rules provide bankruptcy courts the
power to determine the manner in which notices required by the bankruptcy code are provided and
allow parties in interest to request electronic transmission of such notices and to enter orders as
appropriate in jointly administered cases.216 This authority was supplemented by local rules allowing
the court to set appropriate notice requirements and a general order providing that issuance of an
account on the Court’s electronic filing system constitutes waiver of conventional service for that

Id. at 4.
at 5; 11 U.S. Code §105(a).
215 Motion to Establish Case Management Procedures at 5.
216 Fed. R. Bankr. P.2002(m); Fed R. Bankr. P.9007; Fed R. Bankr. P. 9036; Fed R. Bankr. P. 1015(c).
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user.217 The Debtors also provided the court with case law allowing similar Case Management
Procedures.218 The Debtors motion was granted.219

See Local Rule 9074-1(c)(3), (4); General Order M-399 at § II.B.1.
See In re Windstream Holdings, Inc., Case No. 19-22312 (RDD) (Bankr. S.D.N.Y. Feb. 28, 2019); In re Synergy
Pharmaceuticals Inc., Case No. 18-14010 (JLG) (Bankr. S.D.N.Y. Feb. 7, 2019); In re Sears Holdings Corp., Case No. 1823538 (RDD) (Bankr. S.D.N.Y. Nov. 1, 2018); In re Cenveo, Inc., Case No. 18-22178 (RDD) (Bankr. S.D.N.Y. March, 15,
2018); In re Tops Holding II Corp., Case No. 18-22279 (RDD) (Bankr. S.D.N.Y. Feb. 26, 2018); In re 21st 69-23649-rdd Doc
16 Filed 09/16/19 Entered 09/16/19 03:31:34 Main Document Pg 7 of 33; Century Oncology Holdings, Inc., Case No. 1722770 (RDD) (Bankr. S.D.N.Y. June 20, 2017); In re BCBG Max Azria Glob. Holdings, LLC, Case No. 17-10466 (SCC)
(Bankr. S.D.N.Y. Mar. 7, 2017); In re Avaya Inc., Case No. 17-10089 (SMB) (Bankr.S.D.N.Y. Feb. 15, 2017); In re Int’l
Shipholding Corp., Case No. 16-12220 (SMB) (Bankr. S.D.N.Y. Sept. 16, 2016); In re Aéropostale, Inc., Case No. 16-11275
(SHL) (Bankr. S.D.N.Y. June 03, 2016).
219 Order Establishing Certain Notice, Case Management, and Administrative Procedures .pdf, In re Purdue Pharma L.P.,
No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), https://perma.cc/ECE6-E76Q.
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Schedules and Statement of Financial Affairs
Unique to Debtors’ bankruptcy was its financial health. Mass tort litigation spurred the
bankruptcy filing as opposed to more traditional causes such as balance sheet insolvency or cash
flow insolvency. As such, Debtors’ schedules and statement of financial affairs were not of major
import to its reorganization beyond its compulsory filing. Despite this, per Fed. R. Bankr. P.
1007(b) a Debtor must file (1) a schedule of assets and liabilities; (2) a schedule of current income
and expenditures; (3) a schedule of executory contracts and unexpired leases; and (4) a statement of
financial affairs.220 We will explore these filings below.

Schedule of Assets and Liabilities
Schedule A/B
Schedule A/B requires a debtor to list their real and personal property. In its filing, Debtors
listed their real and personal property (as of the petition date) including various bank accounts,
accounts receivable, stock holdings, investments, depreciation, insurance policies, all known assets,
rights to counter-claims, cross-claims, setoffs, and/or refunds with customers and suppliers, or
potential warranty claims against their suppliers. 221
At the time of filing, Debtors had $1,543,275,938 in total property (including cash, cash
equivalents, and financial assets, deposits and prepayments, accounts receivable, investments,
inventory, office furniture, fixtures, and equipment, machinery, real property).222

Chapter 11 – Bankruptcy Basics, U.S. COURTS, https://perma.cc/HS99-4EQD (last visited Apr. 21, 2021).
Global Notes and Statements of Limitation, Methodology, and Disclaims Regarding the Debtors’ Schedules of Assets
and Liabilities and Statements of Financial Affairs, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (RDD)
(Bankr. S.D.N.Y. Oct. 29, 2019) [https://perma.cc/X9LM-647F].
222 Id. at 163.
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Schedule D
Schedule D requires a debtor to list creditors who have claims secured by property.223 In its
filing, the Debtors stated that they are not aware of any secured creditors holding claims against
them, presumably because the Debtors were current on all their secured obligations.224 Despite this,
the Debtors stated that they listed certain UCC-1 lienholders out of an abundance of caution and
omitted realty lessors, utility companies, and other parties that might hold security deposits.225
At the time of filing, the Debtors listed five liens, each of an undetermined amount, all held by
Ikon Financial Services of Macon, Georgia.226
Schedule E/F
Schedule E/F227 requires a debtor to list all creditors holding unsecured claims. In its filing, the
Debtors stated that they used reasonable efforts to report all general unsecured claims, including
claims potentially owed to various tax and regulatory authorities.228 The Debtors also disclosed
information regarding pending litigation, but listed potential claim amounts as undetermined and
marked them as contingent, unliquidated, and disputed.229
At the time of filing, the Debtors’ nonpriority unsecured claims totaled $14,250,045230 while its
priority unsecured claims totaled $1,627,548.231

Id. at 164-65.
Id. at 8.
225 Id. 8-9
226 Id. at 164-65.
227 See generally, id. 164-84.
228 Id. at 9.
229 Id. at 9-10.
230 Id. at 1160.
231 Id. at 184.
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Schedule G
Schedule G requires a debtor to list all their executory contracts and unexpired leases. At the
time of filing, the Debtors listed a total of 3,626 contracts.232 These contracts included, but were not
limited to, agreements with suppliers, staffing agencies, distributors, administrative service providers,
research labs, banks, and consultants.233

Statement of Financial Affairs
On October 29, 2019, Debtor filed its Schedule of Assets and Liabilities and Statement of
Financial Affairs.234 This document provides an overview of the Debtors’ financial health and will
be explored below.
Gross Revenue
From the beginning of the fiscal year (2019) to its Petition Date, the Debtors generated a total of
$999,694,017.44 in gross revenue; with a total of $202, 212,170 of non-business revenue (from
interest, dividends, royalties, or money collected from lawsuits) in that same time.235
Certain Payments or Transfers to Creditors Within 90 Days Before Filing
The Debtors listed each payment or transfer greater than $6,425, other than regular employee
compensation, within 90 days prior to its Petition Date.236 Totaling $333,635,947,237 these payments
were overwhelmingly for professional services, such as payment processing, legal advice, consulting,
data processing, and other expenses typical in the day-to-day of a large corporation.238

Id. at 1579.
See generally, id. 1163-1579.
234 Global Notes and Statements of Limitation, Methodology, and Disclaimers Regarding the Debtors’ Schedules of
Assets and Liabilities and Statements of Financial Affairs, In re Purdue Pharma L.P., et al., Case No. 19-19-23649
(Bankr. S.D.N.Y. Oct. 29, 2019) [https://perma.cc/5K4W-896W].
235 Id. at 15-16.
236 Id. at 33.
237 Id. at 35.
238 See generally, id. 17-152.
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Payments or Other Transfers of Property Made Within 1 Year
The Debtors listed each payment or transfer greater than $6,425 made to an insider or
guaranteed or consigned by an insider within one year prior to its Petition Date.239 These payments
primarily included high-level employee compensation such as payments towards executive
severance, officer/director indemnification, incentive plan payments, expense reimbursements,
employee retirement plan contributions, and auto allowances.240 These payments also included
amounts towards third party support services such as information technology, research and
development services, manufacturing services support, and financial and tax services.241 These
payments totaled $82,515,713.242

See generally, id. 152-92.
Id.
241 Id.
242 Id. at 192.
239
240
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Payments Related to Bankruptcy
The Debtors listed each payment or transfer made within one year prior to its Petition Date to
any person or entity that it consulted about debt consolidation, restructuring, or bankruptcy.243 Four
companies were consulted prior to filing: Alix Partners LLP, Davis Polk and Wardwell LLP, PJT
Partners LP, and Prime Clerk LLC, these payments totaled:244
ENTITY
Alix Partners LLP
Davis Polk and Wardwell LLP
PJT Partners LP
Prime Clerk LLC

DATE RANGE
3/17/19-9/13/19
2/19/19-9/11/19
9/27/18 – 9/14/19
3/15/19-8/8/19
Total

243
244

TOTALS
$11,671,063.00
$37,347,524.00
$3,249,459.00
$1,328,931.00
$53,596,977.00

Id. at 498.
Id. 498-508. These totals were aggregated by the authors.
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DIP Financing
The Debtors’ reorganization was spurred by mass tort litigation rather than balance sheet or
equitable insolvency; given this, debtor-in-possession financing was unnecessary. The Company has
been able to fund its reorganization without the need for post-petition financing and thus never filed
any motions with the court to approve lenders.
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Major Creditor Groups
Due to the numerous creditors in the Debtors’ bankruptcy, including thousands of tort
claimants, to expedite the reorganization, these creditors were separated into groups. These groups
allowed the Debtors to negotiate with similarly situated creditors as a whole, rather than individually,
expediting the reorganization process. How each creditor group is affected by the Debtors’ Plan
and their response to its proposal and confirmation is discussed in the Chapter 11 Plan section.

Official Committee of Unsecured Creditors and Certain Related Parties
Per § 1102(a),245 on September, 27, 2019, the United States Trustee for Region 2 appointed
several unsecured creditors to serve on the Official Committee of Unsecured Creditors (the
“OCC”).246 These creditors include: (1) West Boca Medical Center, (2) CVS Caremark Park D
Services L.L.C. and CaremarkPCS Health, L.L.C., (3) LTS Lohmann Therapy Systems Corporation,
(4) Blue Cross and Blue Shield Association, (5) Pension Benefit Guaranty Corporation, (6) Kara
Trainor, (7) Ryan Hampton, (8) Cheryl Juaire, and (9) Walter Lee Salmons.247
West Boca Medical Center, in Boca Raton, Florida, was one of the first hospitals to argue in
a lawsuit that it should not have to “bear the costs” of the care it continues to provide because of
the opioid crisis.248
CVS Caremark Park D Services L.L.C. and Caremark PCS Health, L.L.C., are among the
Debtors’ fifty largest unsecured claim holders that are not insiders, they collectively hold over

11 U.S.C. §1102(a) https://perma.cc/QF5K-L5AT.
Notice of Appointment of Official Committee of Unsecured Creditors, In re Purdue Pharma L.P., et al., Case No.
19-19-23649 (Bankr. S.D.N.Y. Sept. 27, 2019), https://perma.cc/C76W-3MFM.
247 Id.
248 Alexandra Clough, EXCLUSIVE: Sackler family company pays $7 million for mansion near Boca Raton, THE PALM BEACH
POST, Oct. 25, 2019 (https://perma.cc/F864-EWCN).
245
246
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$24,320,906 in payer rebate claims.249 Payer rebate claims are drug price discounts from the
manufacturer to lower the price of the drug to the company receiving the rebate.250
LTS Lohmann Therapy Systems Corporation is a trade creditor that manufactures a drug
delivery system and has several contracts with the Debtors.251
Blue Cross and BlueShield Association represent a network of Blue Cross Blue Shield
companies that provide health care coverage. Its claim against Purdue ranged from approximately
$69 billion to $79 billion for excess payments for prescription medications used by its health plan
members and for having to cover the costs of illnesses, injuries, and addictions that would “would
not have been incurred but for the actions of the Debtors.”252
Pension Benefit Guaranty Corporation is a wholly owned United States government
corporation and agency whose claims arise under the Employee Retirement Income Security Act for
unfunded benefit liabilities, unpaid minimum funding contributions, and unpaid Title IV insurance
premiums.253
Unique to the OCC is the presence of four private citizens, Kara Trainor, Ryan Hampton,
Cheryl Juaire, and Walter Lee Salmons, who are each victims of opioid addiction. Kara Trainor is
the mother of a child born dependent on opioids. Ryan Hampton is a recovering opioid addict.
Cheryl Juaire lost her son to a heroin overdose after he became addicted to prescription painkillers.
Walter Lee Salmons is helping raise two opioid affected children.254

249 Purdue Pharma L.P. Voluntary Petition, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y.
Sept. 15, 2019), https://perma.cc/84CD-K3F6.
250 Prescription Drug Rebates, Explained, KFF (Jul. 26, 2019), https://perma.cc/5M5A-NPD7.
251 Verified Statement of the Official Committee of Unsecured Creditors, In re Purdue Pharma L.P., et al., Case No. 1919-23649 (Bankr. S.D.N.Y. Oct. 15, 2019), https://perma.cc/7UUL-6U9A.
252 Carla K. Johnson & Geoff Mulvihill, Victims gain a voice to help guide Purdue Pharma bankruptcy, AP (Oct. 6, 2019),
https://perma.cc/BZS9-ZL2V.
253 Supra note 62, at 5.
254 Supra note 63.
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On October 9, 2019, several Native American Tribes filed a motion requesting entry of an
order directing the U.S. Trustee to appoint an official committee of Native American affiliated
creditors comprising Native American tribes, tribal members and/or support organizations, health
organizations or clinics that serve Native American communities.255 Instead, the OCC invited the
tribes to serve as an ex officio member of their committee, which they did upon withdrawing their
motion.256
On October 21, 2019, the OCC granted a request by the Multi-State Government Entities
group to join the OCC in an ex officio capacity, and they designated Cameron County, Texas to act as
an ex officio member.257
On June 18, 2020, the OCC also invited certain public school districts (approximately 13,000
nationwide) to serve as an ex officio member. The public school districts accepted this invitation on
June 19, 2020 and appointed Thornton Township High School District 205 to serve as an ex officio
member of the OCC on the districts’ behalf.258

255 Motion to Appoint Committee of Native American and Native American Affiliated Creditors, In re Purdue Pharma
L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Oct. 9, 2019), https://perma.cc/C3PL-ASUH.
256 Notice of Withdrawal of Motion Seeking Appointment an Official Committee of Native American and Native
American Affiliated creditors, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Nov. 11, 2019),
https://perma.cc/Z2D2-HFTL.
257 Second Amended Verified Statement of the Multi-State Governmental Entities Group, In re Purdue Pharma L.P., et
al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Oct. 9, 2019), https://perma.cc/6WRB-5JVA.
258 Plan Disclosure Statement, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Mar. 15,
2021),https://perma.cc/9EAC-HNTF [hereinafter referred to as Plan Disclosure Statement].
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Ad Hoc Committee of Government and Other Contingent Litigation Claimants
Prior to filing its petition, the Debtors reached an agreement-in-principle with twenty-four
states, five U.S. territories, the plaintiffs’ executive committee of In re National Prescription Opiate
Litigation, Case No. 17-md-02804, MDL No. 2804 (N.D. Ohio), and certain U.S. cities and countries
(the Settlement Group”). In September 2019, representatives of the Settlement Group formed the
Ad Hoc Committee of Government and Other Contingent Litigation Claimants (the “Ad Hoc
Committee”).259 As representatives, the Ad Hoc Committee appointed: (1) the states of (a) Florida,
(b) Georgia, (c) Louisiana, (d) Michigan, (e) Mississippi, (f) New Mexico, (g) Ohio, (h) Tennessee, (i)
Texas, (j) Utah; (2) the counties of: (a) Broward (FL), (b) Santa Clara (CA), King (WA),
Huntington/Cabell (WV); (3) the cities of: (a) Chicago and (b) Philadelphia; and (4) the Muscogee
(Creek) Nation.260

Motion of the Debtors for an Order Approving Stipulation and Agreed Order Granting Joint Standing to Prosecute
Claims and Causes of Action Related to the Debtors’ Insurance Coverage to (1) The Official Committee of Unsecured
Creditors and (2) the Ad Hoc Committee of Governmental and other Contingent Litigation Claimants, In re Purdue
Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Jan. 6, 2021), https://perma.cc/9ZEE-HP8V.
260 Ad Hoc Committee’s Verified Statement, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y.
Oct. 10, 2019), https://perma.cc/4J3D-7KVD.
259
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Ad Hoc Group of Non-Consenting States
During the Debtors’ negotiations with the federal government to resolve its civil and
criminal investigations regarding its past opioid marketing practices, a group of states and the
District of Columbia banded together to voice their dissatisfaction with the proposed settlement (the
“Non-Consenting States”).261 The Non-Consenting States includes: California, Colorado,
Connecticut, Delaware, the District of Columbia, Hawaii, Idaho, Illinois, Iowa, Maine, Maryland,
Massachusetts, Minnesota, Nevada, New Hampshire, New Jersey, New York, North Carolina,
Oregon, Pennsylvania, Rhode Island, Vermont, Virginia, Washington, and Wisconsin.262
Chiefly, the Non-Consenting States argue that the proposed settlement lacks any
acknowledgement of wrongdoing on behalf of the Sackler family, does not require public disclosure
of evidence, and does not enjoin the Sackler’s from future misconduct.263

261 The States’ Coordinated Opposition to the Debtors’ Motion for Preliminary Injunction of States’ Law Enforcement
Actions Against The Sacklers, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Oct. 4, 2019),
https://perma.cc/TX5Y-BBBW.
262 Id. at 1.
263 Id. at 9.
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Ad Hoc Committee of NAS Babies
The Ad Hoc Committee of NAS (neonatal abstinence syndrome) Babies (“NAS Babies”)
members are individual babies (and/or guardians of those babies) who were born opioid dependent
because their mothers were either prescribed opioids during pregnancy or obtained opioids on the
secondary market.264

Verified Statement of the Ad Hoc Committee of NAS Babies, In re Purdue Pharma L.P., et al., Case No. 19-1923649 (Bankr. S.D.N.Y. Oct. 22, 2019), https://perma.cc/TF3J-2UCJ.
264
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Ad Hoc Group of Individual Victims
Formed in October 2019, the Ad Hoc Group of Individual Victims (the “Ad Hoc Group”)
hold general unsecured claims against the Debtors.265 The Ad Hoc Group contains eight members
who each hold an unliquidated unsecured claim of at least $2.5 million arising from personal injury
as a result of opioid addiction.266 Their backgrounds vary but each has either been personally
affected by or had a loved one affected by opioid addiction.267

265 Verified Statement of the Ad Hoc Group of Individual Victims, In re Purdue Pharma L.P., et al., Case No. 19-1923649 (Bankr. S.D.N.Y. Oct. 25, 2019), https://perma.cc/UPC2-KJ2G.
266 Id. at 6.
267 See generally id. 1-4.
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Multi-State Governmental Entities Group
The Multi-State Governmental Entities Group (the “MSGE Group”) consists of
approximately 1,317 entities: comprising 1,245 cities, countries, and other governmental entities,
nine (9) tribal nations, thirteen (13) hospital districts, thirty-two (32) medical groups, and two (2)
funds, across thirty-eight (38) states, all with claims against the Debtors.268 Collectively, the entities
hold unliquidated claims in the billions of dollars against the Debtors’ estate arising from their role
in the opioid crisis.269 This group is primarily comprised of non-federal public creditors and
comprises the other major public group-claimant in negotiations with the Debtors regarding its
reorganization.

268 Verified Statement of the Multi-State Governmental Entities Group, In re Purdue Pharma L.P., et al., Case No. 1919-23649 (Bankr. S.D.N.Y. Oct. 9, 2020), https://perma.cc/W5H9-C47J.
269 Id. at 2.
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Ad Hoc Group of Self-Funded Health Plans
The Ad Hoc Group of Self-Funded Health Plans (the “SF Group”) consists of four selffunded union plans, which each hold unliquidated claims against the Debtors that it values in the
billions, arising from its increased costs due to the opioid crisis.270

Statement of the Ad Hoc Group of Self-Funded Health Plans, In re Purdue Pharma L.P., et al., Case No. 19-1923649 (Bankr. S.D.N.Y. June 6, 2020), https://perma.cc/9V55-XB4A.
270
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Ad Hoc Committee on Accountability
The Ad Hoc Committee on Accountability (the “Committee on Accountability”) is not a
committee as that term is used in § 1102,271 but represents five members with unliquidated,
unsecured claims based on wrongful death and the loss of consortium claims against the Debtor.272
These creditors separated themselves from other similarly situated creditors due to their focus on
accountability though the publication of all of Debtors’ internal documents, privileged and
nonprivileged, as well as all communications between Debtors and the Sackler family.273

11 U.S.C. § 1102 https://perma.cc/7LJK-E5KX.
Statement of the Ad Hoc Committee on Accountability, In re Purdue Pharma L.P., et al., Case No. 19-19-23649
(Bankr. S.D.N.Y. May, 28, 2020), https://perma.cc/XE4C-3HHJ.
273 Natasha Lennard, The New Fight to Hold Purdue Pharma and the Sacklers Accountable for the Opioid Crisis, THE INTERCEPT
(July 20, 2020), https://perma.cc/CHW9-A8TH.
271
272
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Ad Hoc Group of Hospitals
The Ad Hoc Group of Hospitals is a group of hundreds of hospitals across the United
States (approximately 10% of all U.S. hospitals) that have each treated (and continue to) patients for
conditions related to the use of opiates manufactured by the Debtors.274 The Ad Hoc Group of
Hospitals claims it has incurred (and will continue to incur for the indefinite future) millions of
dollars in damages associated with the expenses of treating opioid addiction; which are particularly
debilitating for smaller hospitals in rural areas.275

274 Statement of Ad Hoc Group of Hospitals, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y.
Dec. 3, 2019), https://perma.cc/YX85-4CPQ.
275 Id. 3-4.
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Bankruptcy Transactions
Preliminary Injunction and Voluntary Injunction
On September 18, 2019, the Debtors filed a Motion for a Preliminary Injunction (the
“Preliminary Injunction Motion”) to stay active litigation against the Debtors, their current or
former owners (including any trusts and their respective trustees and beneficiaries), officers,
directors, employees, and associated entities, arising out of the Debtors’ manufacture, distribution,
and sale of prescription opioid medications.276 The Preliminary Injunction also sought entry of a
voluntary injunction (the “Voluntary Injunction”) against the Debtors, enjoining them from
promoting opioid products and providing financial support to third parties for the purpose of
promoting opioids.277
On October 11, 2019, the court issued an order pursuant to 11 U.S.C. § 105(a) granting, in
part, the Debtors’ motion for a preliminary injunction.278 The court ordered that the Governmental
Defendants and the Private Defendants are prohibited from—primarily—the commencement or
continuation of their actions or proceedings against the Debtors (or related parties) that were or
could have been commenced before the commencement of the instant case related to the Debtors’
prescription opioid business.279 This injunction would last through November 6, 2019.280
This order was extended on November 6, 2019.281 Notably, some entities were excluded
from this order’s enjoinment, but they opted to abide by its term until December 19, 2019,

Plan Disclosure Statement at 40-41.
Plan Disclosure Statement at 41.
278 Order Pursuant to 11 U.S.C. § 105(a) Granting, In Part, Motion for a Preliminary Injunction, Purdue Pharma L.P., et
al. v. Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case
No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/YKQ5-8ARQ].
279 Id. at 5.
280 Id. at 4.
281 Second Amended Order, Purdue Pharma L.P., et al. v. Commonwealth of Massachusetts, et al., Adv. Pro. No. 1908289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019)
[https://perma.cc/R87Q-USSA].
276
277
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including: Arizona, the Ad Hoc Group of Non-Consenting States, and the Multi-State
Governmental Entities Group (the “Potential Opt-Out Parties”).282
The Order was extended, again, on November 20, 2019.283 As in the second order, the
Potential Opt-Out Parties opted to abide by the order’s injunction.284 This order allowed a Potential
Opt-Out Party to opt out by filing a withdrawal notice with the court on either December 19, 2019
or February 21, 2020.285 If done, the exiting parties will then be bound by the same terms imposed
on other parties by the November 6 order until April 8, 2020.286
The order was again extended on December 9, 2019.287 Here, the same terms of the
injunction apply, and the Potential Opt-Out Parties agreed to abide by the terms of the second order
granting preliminary injunction.288 The order was extended, in the same terms, several times—the
most recent being on March 26, 2021. 289

Id. at 5.
Third Amended Order Granting Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v. Commonwealth of
Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD) (Bankr.
S.D.N.Y. Oct. 3, 2019) [https://perma.cc/93R3-RA4Z].
284 Id. at 5.
285 Id. at 6.
286 Id.
287 Fourth Amended Order Granting Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v. Commonwealth
of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD)
(Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/4T6S-2Z6R].
288 Id. at 6.
289 Sixteenth Amended Order Granting Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v.
Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Mar. 26, 2021) https://perma.cc/DK3T-9D38.
282

283
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Monitor
In consult with the Official Committee, the Ad Hoc Group of Non-Consenting States, and
the Ad Hoc Committee of Governmental Entities, the Debtors agreed to retain a monitor, to
oversee its compliance with the Voluntary Injunction and issue reports of that compliance every
ninety days.290 The Monitor produced four reports and found no issues with the Debtors’
compliance.291

290 Proposed Amended Preliminary Inunction, In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD) (Bankr.
S.D.N.Y. Nov. 6, 2019), https://perma.cc/ETJ2-QNZ7.
291 Plan Disclosure Statement at 42.
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Automatic Stay
Upon filing a Chapter 11 case, a stay is automatically imposed under § 362(b).292 The automatic
stay is intended to give the debtor breathing room by stopping all collection efforts, harassment, and
foreclosure actions.293 The goal of the automatic stay is to allow the debtor to develop a
reorganization plan outside of the pressure from creditors or claimants, such that the most effective
plan may be created for the debtor and its estate.294 The stay may be lifted or modified, provided
that the movant shows “cause” such as bad faith.295 The burden is on the movant to prove cause to
lift the stay; if done, the burden is then shifted to the debtor to rebut the movant’s assertions.296

11 U.S.C. § 362 https://perma.cc/GF76-8958.
In re Soares, 107 F.3d 969, 977 (1st Cir. 1997).
294 3 COLLIER ON BANKRUPTCY ¶ 362.03 (16th ed. 2019).
295 In re Project Orange Associates, LLC, 432 B.R. 89, 103 (Bankr. S.D.N.Y. July 1, 2010).
296 In re Mosher, 578 B.R. 765, 772 (Bankr. S.D. Tex. 2017); see also Cates, Nathan and Foody, Landon, "Drilling for
Success: An Excavation of Sanchez Energy Corporation’s Ch. 11 Reorganization", 82 (2020). Chapter 11 Bankruptcy Case
Studies., https://trace.tennessee.edu/utk_studlawbankruptcy/60, https://perma.cc/JY5P-TSP2.
292
293
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Motions for Relief from Automatic Stay
TIG Motion
On December 30, 2019, Ironshore Specialty Insurance Company, formerly known as TIG
Specialty Insurance Company (“TIG”), filed a motion for relief from the automatic stay.297 TIG
argued that it is party to an arbitration proceeding with Purdue Pharma L.P. (and its other
subsidiaries), in connection with the parties’ respective rights and obligations under an insurance
policy; which, it claimed, is mandatory and non-core. 298 Given this, TIG argued the automatic stay
should be lifted and the arbitration should be allowed to proceed.299
In response, the Debtors argued that TIG failed to show that cause exists to lift the stay and that
lifting the stay would impose unnecessary costs and distractions on the Debtors as well as frustrating
its reorganization.300 Following this, the OCC filed in joinder to the Debtors’ motion, echoing their
arguments that lifting the stay would frustrate the Debtors’ reorganization.301 The Ad Hoc
Committee also filed a statement in support of the Debtors’ objection.302
A hearing on this issue was scheduled for March 24, 2021 but was adjourned to a date to be
determined; at the time of writing that date had not yet been set.303

297 Ironshore Specialty Insurance Company’s Notice of Motion and Hearing, In re Purdue Pharma L.P., et al., Case No.
19-19-23649 (Bankr. S.D.N.Y. Dec. 30, 2019), https://perma.cc/7K33-WHSN.
298 Id. at 2.
299 Id.
300 Debtor’s Objection to TIG’s Motion for Relief From the Automatic Stay, In re Purdue Pharma L.P., et al., Case No.
19-19-23649 (Bankr. S.D.N.Y. Jan. 17, 2020), https://perma.cc/4C73-DP7Y.
301 Objection of the Official Committee of Unsecured Creditors to the Motion of Ironshore Specialty Insurance
Company for Relief from the Automatic Stay and Joinder to the Debtors’ Objection to Such Motion, In re Purdue
Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Jan. 17, 2020), https://perma.cc/5SP3-WJPW.
302 Ad Hoc Committees Statement in Support of Debtors Objection to TIGs Motion for Relief from the Automatic
Stay, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Jan. 17, 2020), https://perma.cc/G94XBC7J.
303 Notice of Adjournment of Hearing Regarding Ironshore Specialty Insurance Company, Formerly Known as TIG
Specialty Insurance Company’s Motion or Relief from the Automatic Stay, In re Purdue Pharma L.P., et al., Case No.
19-19-23649 (Bankr. S.D.N.Y. Mar. 22, 2021), https://perma.cc/55G2-VSGM.
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Allergan Finance LLC
On March 11, 2020, Allergan Finance LLC (“Allergan”) filed a motion explaining that they (as
Plaintiffs)—along with the Debtors (as Defendants)—are party to prescription opioid litigation in a
New York State court claiming public nuisance. 304 That litigation set a liability-only phase and
Allergen asks the court to confirm that the automatic stay does not prohibit inclusion of the Debtors
on the jury verdict form to apportion fault; or alternatively, to grant relief for this limited purpose.305
The People of the State of New York filed an opposition brief to Allergan’s motion,306 as did the
Debtors,307 the Non-Consenting States,308 the OCC,309 and the Ad Hoc Committee.310 In response,
Allergan filed an Omnibus Reply arguing that none of the above briefs disclosed a case where the
automatic stay prevented a debtor from being added to a verdict form for purposes of
apportionment.311
At the time of writing, an order had yet to be issued.

304 Allergan Finance LLC’s Motion for Relief from Stay, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr.
S.D.N.Y. Mar. 11, 2020), https://perma.cc/P94J-JFEF.
305 Id.
306 Opposition of New York Plaintiffs to Defendants’ (Allergan) Motion for Relief from the Automatic Stay, In re
Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Mar. 24, 2020), https://perma.cc/2Y5E-39SK.
307 Debtors’ Objection to Co-Defendants’ Motion for Relief from the Automatic Stay, In re Purdue Pharma L.P., et al.,
Case No. 19-19-23649 (Bankr. S.D.N.Y. April 15, 2020), https://perma.cc/962W-LXNB.
308 Opposition of the Non-Consenting States to Opioid Defendants’ Motion for Relief from the Automatic Stay, In re
Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. April 15, 2020), https://perma.cc/XT9C-MLVU.
309 Objection of the Official Committee of Unsecured Creditors to the Motion for Relief from the Automatic Stay, In re
Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. April 15, 2020), https://perma.cc/YCM9-8HYN.
310 Ad Hoc Committee’s Objection and Joinder in the Debtors’ Objection to Co-Defendants’ Motion for Relief from the
Automatic Stay, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. April 15, 2020),
https://perma.cc/JKH9-D42B.
311 Defendants’ Omnibus Reply in Support of Motion for Relief from the Automatic Stay, In re Purdue Pharma L.P., et
al., Case No. 19-19-23649 (Bankr. S.D.N.Y. April 19, 2020), https://perma.cc/PP2V-KAYE.
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Bar Date
Per Fed. R. Bankr. P. 3003(c)(2), all parties whose claims are “not scheduled or scheduled as
disputed, contingent, or unliquidated” must file a proof of claim by the bar date in order to be
“treated as a creditor.” 312 The Debtors requested that the deadline for filing proofs of claim (the
“General Bar Date”) be set as June 30, 2020 or thirty days after entry of any order authorizing the
rejection of an executory contract or unexpired lease as the deadline for claimants to assert claims
for such actions.313 Next, the Debtors sought that the deadline for creditors with claims affected by
the Debtors’ filing of its Schedule of Assets and Liabilities and/or Statement of Financial Affairs
(collectively, the “Schedules”) to be the General Bar date or 30 days after being serviced.314 This
motion also set out the proposed procedures for filing proofs of claims,315 notice of the Bar Dates
publication notice for unknown claimants; 316 and proposed proof of claims forms for (1)
Governmental Opioid Claimants, (2) Personal Injury Claimants, (3) General Opioid Claimants, and
(4) Non-Opioid Claimants.317
An order approving this motion was entered on February 3, 2020.318

312 Debtors’ Motion for Entry of an Order (I) Establishing Deadlines for Filing Proofs of Claim and Procedures Relating
Thereto, (II) Approving the Proof of Claim Forms, and (III) Approving the Form and Manner of Notice Thereof, In re
Purdue Pharma L.P., et al., Case No. 19-19-23649, 5 (Bankr. S.D.N.Y. Jan. 3, 2020), https://perma.cc/BP85-PC5E.
313 Id.
314 Id.
315 Id.
316 Id. at 6.
317 Id.
318 Order Establishing (I) Deadlines for Filing Proofs of Claim and Procedures Relating Thereto, (II) Approving the
Proof of Claim Forms, and (III) Approving the Form and Manner of Notice Thereof, In re Purdue Pharma L.P., et al.,
Case No. 19-19-23649, 5 (Bankr. S.D.N.Y. Feb. 3, 2020), https://perma.cc/STV6-A4QN.
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Motion to Extend the Bar Date
In response to COVID-19, the Debtors filed a motion to extend the General Bar Date by 30
days to July 30, 2020.319 The Debtors wanted to accommodate any potential delays in notice or
response brought on by the Covid-19 pandemic.320 In their motion, the Debtors stated that they
affirmed their commitment to resolving its cases as expeditiously as possible and, as such, were only
asking for 30 days as opposed to 90; though even 30, it admitted, had been met with reluctance by
its major creditor groups.321
A series of filings were filed in response to this motion. The Ad Hoc Committee filed a
limited objection to the 30-day extension, asking instead that the General Bar Date be extended by
90 days.322 Likewise, the Non-Consenting States filed a limited objection asking the court to extend
the bar date to until September 30 citing COVID-19 disruptions.323 Conversely, the Ad Hoc
Committee of Governmental and Other Contingent Litigation Claimants argued that the bar date
extension is costly and unlikely to benefit potential claimants.324

Debtors’ Motion for Entry of an Order (I) Extending the General Bar Date for a Limited period and (II) Approving
Form and Manner of Notice Thereof, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. May 5,
2020), https://perma.cc/973C-W9EE.
320 Id. at 4-5.
321 Id. at 5.
322 Limited Objection of the Ad Hoc Committee on Accountability to the Debtors’ Motion for an Order Extending
General Bar Date, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. May 28, 2020),
https://perma.cc/8WJJ-RFZX.
323 Limited Objection of the Non-Consenting States to Debtors’ Motion, In re Purdue Pharma L.P., et al., Case No. 1919-23649 (Bankr. S.D.N.Y. May 31, 2020), https://perma.cc/P4PG-SAW8.
324 Ad Hoc Committee’s Objection to Requests to Extend the Bar Date, In re Purdue Pharma L.P., et al., Case No. 1919-23649, 3-4 (Bankr. S.D.N.Y. May 31, 2020), https://perma.cc/J89G-EBTQ.
319
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Several of the major creditor groups filed motions in support of the Debtors’ motion,
including the Multi-State Governmental Entities,325 the Ad Hoc Group of Individual Victims,326 and
the OCC.327 On June 3, 2020, the court entered an order extending the bar date to July 30, 2020.328

Multi-State Governmental Entities Group Statement in Support of the Debtors’ Motion for Entry of an order
Extending the General Bar Date for a Limited Period and Approving the Form of Notice Thereof, In re Purdue Pharma
L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. May 28, 2020), https://perma.cc/AAZ4-KKG3.
326 Statement of the Ad Hoc Group of Individual Victims (I) in Support of the Debtors’ Motion for Entry of an Order
Extending the General Bar Date for a Limited Period and (II) Objecting to Requests for Entry of an Order Extending
Bar Date by Ninety Days, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. May 31, 2020),
https://perma.cc/XYX5-T4TN.
327 Statement of the Official Committee of Unsecured Creditors in Response to Letter Briefs Requesting Extension of
Bar Date, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. May 31, 2020),
https://perma.cc/9JH9-8JPA.
328 Order Granting Motion (I) Extending the General Bar Date for a Limited Period, and (II) Approving the Form and
Manner of Notice Thereof, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. June 3, 2020),
https://perma.cc/UP9P-YPMB.
325
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Prepetition Reimbursement Agreement with Ad Hoc Committee
On October 29, 2019, the Debtors filed a motion to assume the Reimbursement Agreement of
the Ad Hoc Committee. 329 In it, the Debtors argued that the proposed settlement it was seeking for
the pending litigation against it was only possible due to the prepetition organization of claimants,
such as the Ad Hoc Committee.330 Further, the Debtors contend that the Professionals serving the
Ad Hoc Committee were selected due to their knowledge of navigating large and complex
restructurings.331 Therefore, the Debtors argue, it is crucial that it be allowed to fund the payment of
these professionals to facilitate the confirmation of a plan of reorganization, which is conditioned on
reaching a settlement.332 On December 20, 2019, the court entered an order authorizing the
Debtors to assume the reimbursement agreement and pay the fees and expenses of the Ad Hoc
Committee’s professionals.333

329 Debtor’s Motion to Assume the Prepetition Reimbursement Agreement with Ad Hoc Committee and to Pay the Fees
and Expenses of the Ad Hoc Committee’s Professionals, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr.
S.D.N.Y. Oct. 29, 2019), https://perma.cc/W96P-J89M
330 Id. at 2.
331 Id. at 3-4.
332 Id. at 2-5.
333 Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad
Hoc Committee’s Professionals, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Dec. 20,
2019), https://perma.cc/Y59K-F6HC.
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Adversary Proceedings
Stacey Bridges and Creighton Bloyd et al. v. Purdue Pharma L.P., et al.
On December 10, 2020, Attorneys Frank Ozment and Roderick Graham filed a class action
on behalf of Plaintiffs Stacy Bridges and Creighton Bloyd as well as others similarly situated against
the Debtors.334 The plaintiffs sought to establish a trust for the victims of the Debtor’s conduct in
in the opioid crisis to facilitate their recovery. The trust would be funded to provide subsidized
access to therapeutic counseling and medicine assisted treatment for opioid addiction to facilitate
their recovery.335 The plaintiffs referenced the settlement agreement between the Debtor and the
United States, which at that point had received conditional approval from the Bankruptcy Court.336
The complaint alleged that the proposed settlement would be inadequate to treat people like
Stacy Bridges, who personified the Debtor’s typical victim in that she developed a heroin addiction,
due to the settlement’s reliance on” medicine assisted treatment” at the exclusion of “therapeutically
focused counselling.”337 For victims like Creighton Bloyd, who managed to avoid a heroin
addiction, medicine assisted treatment was also likely to be required for the foreseeable future. Mr.
Bloyd will have to pay out of pocket for this treatment, despite having medical insurance, while the
settlement agreement does not require the Debtors to subsidize these costs for victims.338 Given
this, the Plaintiffs sought to require the Debtors to establish a directed trust for the benefit of opioid
addicted persons, such as Ms. Bridges and Mr. Bloyd, who have filed a claim in the instant
bankruptcy.339
334

Complaint against Purdue Pharma L.P., et al., filed by Frank Ozment on behalf of Stacy Bridges and Creighton Bloyd
et al., Adversary Case 20-07027, In re Purdue Pharma L.P., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Dec. 11, 2020)
[[https://perma.cc/RMA6-77P2].
335 Id. at 1.
336 Id. at 2.
337 Id.
338 Id. at 5.
339 Id. at 8. Later, this complaint was amended to include Creighton Bloyd and Charles Fitch on behalf of themselves and
others similarly situated to them as plaintiffs, as well as WalMart, Inc. and McKinsey & Co. as defendants for their
contribution with Debtor in the marketing and distribution of opioids. Amended Adversary Proceeding Complaint,

70

Aviro Health L.P. et al. v. AIG Specialty Insurance Company (f/k/a American International
Specialty Lines Insurance Company) et al.
Out of concern that the Debtors available coverage under its insurance policies would be
dwarfed by the liability it faced related to the opioid mass tort claims, Debtors brought an action to
give all parties in interest clarity about the scope of insurance coverage as well as the availability and
amount of proceeds in its insurance policies.340 The Plaintiffs sought a declaration of the rights,
duties, and liabilities of the insurer-Defendants under the Debtors’ prepetition insurance contracts
and to direct to the insurer-Defendants to indemnify the Debtors or pay damages arising out of the
opioid claims.341 These Plaintiffs included (1) certain Debtors in the bankruptcy, (2) the Official
Committee of Unsecured Creditors appointed in the Chapter 11 Cases, and (3) the Ad Hoc
Committee of Governmental and Other Contingent Litigation Claimants in the Chapter 11 Cases.

filed by James Franklin Ozment I on behalf of Charles Daniel Fitch, Bloyd Creighton, Others Similarly Situated,
Adversary Proceeding No. 20-0727-rdd, In re Purdue Pharma, L.P., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Dec.
11, 2020) [https://perma.cc/U7JC-8VWF]. As of April 6, 2021, a second stipulation and agreed order was signed that
extended the deadline for Defendants to answer or otherwise response to the amended complaint. The pre-trial
conference is currently scheduled for June 16, 2021. Second Stipulation and Agreed Order signed on 4/2/2021
Extending the Deadline for Defendants to Answer or Otherwise Respond to the Amended Complaint, filed by Davis
Polk & Wardell LLP, Case No. 19-23649 (RDD), In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr.
S.D.N.Y. Dec. 11, 2020) [https://perma.cc/SM9G-URDP].
340 Adversary case 21-07005. Complaint against AIG Specialty Insurance Company (f/k/a American International
Specialty Lines Insurance Company), Allied World Assurance Company, Ltd., American Guarantee and Liability
Insurance Company, American International Reinsurance Company (f/k/a Starr Excess Liability Insurance International
Limited), Arch Reinsurance Ltd., Aspen American Insurance Company, Certain Member Companies of the International
Underwriting Association of London Subscribing to Policy No. 823/KE0002108, Chubb Bermuda Insurance Ltd.
(f/k/a ACE Bermuda Insurance Ltd.), Evanston Insurance Company, Gulf Underwriters Insurance Company, HDI
Global SE (f/k/a Gerling-Konzern General Insurance Company), Ironshore Specialty Insurance Company (f/k/a TIG
Specialty Insurance Company), Liberty Insurance Corporation, Liberty Mutual Fire Insurance Company, Liberty Mutual
Insurance Company, Liberty Mutual Insurance Europe SE (f/k/a Liberty International Insurance Company), National
Union Fire Insurance Company of Pittsburgh, PA, Navigators Specialty Insurance Company, North American Elite
Insurance Company, St. Paul Fire and Marine Insurance Company, Steadfast Insurance Company, Swiss Re
International S.E. (f/k/a SR International Business Insurance Company also f/k/a Zurich Reinsurance (London)
Limited, Tenecom Limited (f/k/a Winterthur Swiss Insurance Company), XL Bermuda Ltd. (f/k/a XL Insurance
Company, Ltd.), XL Insurance America, Inc. (Fee Amount $ 350.). Nature(s) of Suit: (14 (Recovery of money/property other)) Filed by Paul E. Breene on behalf of Avrio Health L.P., Purdue Pharma Inc., Purdue Pharma L.P., Purdue
Pharma Manufacturing L.P., Purdue Pharmaceutical Products L.P., Purdue Pharma of Puerto Rico, Purdue Transdermal
Technologies L.P., Rhodes Pharmaceuticals L.P., Rhodes Technologies, In re Purdue Pharma L.P. et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Dec. 11, 2020) [[https://perma.cc/C7J9-BQXF].
341 See generally id.
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Plaintiffs claimed that such a declaration and understanding would enable all stakeholders to
better negotiate regarding the structure and terms of a plan of reorganization, specifically allocation
of creditor recoveries, as well as secure all insurance proceeds that Debtors are entitled arising from
the opioid tort claims.
Following, Defendants Liberty Mutual Insurance Company, Liberty Mutual Fire Insurance
Company, and Liberty Insurance Corporation filed a Motion to Withdraw the Reference of the
Adversary Proceeding.342 28 U.S.C. § 157(b) permits matters that have been automatically referred
to a bankruptcy court to be returned to and heard by the district court.343 Here, the Defendants
argued that because Plaintiff-Debtors’ claims are “non-core” because they do not depend on
bankruptcy laws the court is prohibited from issuing a final judgement.344 Further, the Defendants
claimed that these non-core claims are unnecessary to the Debtors’ reorganization. 345 Given this,
they argued that the proceedings should be withdrawn to the district court for the Southern District
of New York.346 Later, a host of the Debtor’s other insurers would file a Joinder in Motion to
Withdraw the Reference, joining the Motion to Withdraw the Reference filed by the above
Defendants.347

342 Motion to Withdraw the Reference of Adversary Proceeding, Liberty Insurance Corporation, Liberty Mutual Fire
Insurance Company, Liberty Mutual Insurance Company, Adv. Proc. No. 21-07005 (RDD), In re Purdue Pharma L.P. et
al, Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Mar. 22, 2021) [https://perma.cc/46TJ-SJZN].
343 28 U.S.C. § 157 https://perma.cc/FL56-CQM6.
344 Id.
345 Id. at 8-14.
346 Memorandum of Law in Support of Motion to Withdraw the Reference, ), In re Purdue Pharma L.P. et al, Case No.
19-23649 (RDD) (Bankr. S.D.N.Y. Mar. 22, 2021), https://perma.cc/4PZP-CVHE.
347 Specifically, these Defendants include SR International Business Company SE, formerly known as SR International
Business Insurance Company Limited, Chubb European Group SE, formerly known as ACE Insurance S.A.-N.V, QBE
UK Limited, formerly known as QBE International Insurance Company Limited, Darag Insurance UK Limited,
formerly known as The Underwriter Insurance Company Limited, Zurich Specialties London Limited, formerly known
as Zurich Reinsurance (London) Limited, XL Bermuda, Ltd., AIG Specialty Insurance Company, successor to American
International Specialty Lines Insurance Company, New Hampshire Insurance Company, and American International
Reinsurance Company, successor to Starr Excess Liability Insurance International Limited, North American Elite
Insurance Company, Aspen American Insurance Company, XL Insurance America, Inc., and National Union Fire. See
Notice of Certain Defendants’ Joinder in Motion to Withdraw the Reference, Adv. Pro. No. 21-07005, In re Purdue
Pharma L.P., et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. April 5, 2021) [https://perma.cc/K86Q-Z3RW]. Arch
Reinsurance Ltd. would later file a Joint Motion to Withdraw the Reference of Adversary Proceeding As Against
Movants in the Event That the Court Denies the Liberty Mutual Withdrawal Motion; see Joint Motion to Withdraw the
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At the time of writing an order had not been issued regarding the motion to withdraw and
the adversary proceeding is still ongoing.

Reference of Adversary Proceeding As Against Movants in the Event That the Court Denies the Liberty Mutual
Withdrawal Motion, Adv. Case No. 21-07006-rdd, In re Purdue L.P., et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y.
April 5, 2021) [https://perma.cc/HZ9U-78AF].

73

Purdue Pharma L.P. et al. v. Commonwealth of Massachusetts et al.
The Debtors, 348 under Rules 7001(7) and 7065 of the Federal Rules of Bankruptcy
Procedure and section 105 of title 11 of the United States Code, brought this adversary proceeding
to:349
(1) enjoin governmental defendants350 from the commencement or
continuation of their active proceedings against the Debtors that
were or could have been commended before the commencement of
the instant case, as well as the commencement or continuation of any
other actions against the Debtors alleging substantially similar facts or
causes of actions, if not otherwise subject to the automatic stay, then
at least for a period of 270 days from the issuance of the injunction,
and
(2) enjoin the governmental defendants and the private defendants351
in the instant adversary proceeding from the commencement or
continuation of their active judicial, administrative, or other actions
or proceedings, and the commencement or continuation of other
actions alleging substantially similar facts or causes of actions as those
alleged in the actions against former or current (a) owners (including
any trusts and their respective trustees and beneficiaries), (b)
directors, (c) officers, (d) employees, and (e) associated entities of the
Debtors that were or could have been commenced before the
commencement of this case, if not otherwise subject to the automatic
stay, then for period of 270 days form the issuance of the
injunction.352
The Plaintiff-Debtors argued that without this relief, defending the pending actions will
thwart the goals of the bankruptcy by draining the estate.353 The Debtors also contend that the
pending actions, the vast majority of which are brought by governmental agencies, do not fall within

348 Plaintiff Debtors in this case include: Purdue Pharma, Inc., Purdue Transdermal Technologies L.P., Purdue Pharma
Manufacturing L.P., Purdue Pharmaceuticals L.P., Purdue Pharma of Puerto Rico, Purdue Pharmaceutical Products,
L.P., Rhodes Pharmaceuticals L.P., Rhodes Technologies, and Aviro Health L.P.
349 Complaint for Injunctive Relief, Purdue Pharma L.P. et al. v. Commonwealth of Massachusetts et al., Adv. Pro. Case
No. 19-08289 (RDD), In re Purdue Pharma L.P. et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Sept. 18, 2019)
[https://perma.cc/E7PY-FCWQ].
350 See Exhibit A, Complaint for Injunctive Relief.
351 See Exhibit B, Complaint for Injunctive Relief.
352 Supra note 345, at 24-25.
353 Id. at 26.
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the “police power” exception to the automatic stay contained in 11 U.S.C. § 362(b)(4).354 The
Plaintiff-Debtors argued that there is a reasonable likelihood of a successful reorganization only if the
105(a) injunction is granted (even if the automatic stay does not apply).355
A consortium of some Massachusetts Municipalities, along with other governmental entities
(the “Municipality Consortium”)356 filed a motion in opposition to the Sackler Family’s (nonDebtor) motion for a preliminary injunction.357 The Municipality Consortium argued that the
injunction should be denied to the extent that it seeks to enjoin state court actions brought against
the Sackler Family.358 The Municipality Consortium argued, among other things, that the
bankruptcy court lacks (1) subject matter jurisdiction and (2) authority under Article III to enjoin
their claims.359

Id. at 27.
Id.
356 This Opposition was filed on behalf of a series of cities and towns in Massachusetts and other states, as follows: City
of Cambridge v. Purdue Pharma L.P., et al., No. 1984CV02854 (Dkt. #1) at 32-34, 96-97; Town of Canton v. Purdue
Pharma L.P., et al., No. 1984CV01615 (Dkt. #1) at 30-31, 92-93; City of Chicopee v. Purdue Pharma L.P., et al., No.
1984CV01621 (Dkt. #1) at 30-31, 94-96; City of Framingham v. Purdue Pharma L.P., et al., No. 1984CV01487 (Dkt.
#1) at 30-31, 92-93; City of Gloucester v. Purdue Pharma L.P., et al., No. 1984CV01351 (Dkt. #1) at 30-31, 91-92; City
of Haverhill v. Purdue Pharma L.P., et al., No. 1984CV01311 (Dkt. #1) at 30-31, 92-93; Town of Lynnfield v. Purdue
Pharma L.P., et al., No. 1984CV01330 (Dkt. #1) at 29-30, 92-93; Town of Natick v. Purdue Pharma L.P., et al., No.
1984CV02002 (Dkt. #1) at 30-31, 92-93; Town of Randolph v. Purdue Pharma L.P., et al., No. 1984CV02573 (Dkt. #1)
at 33-34, 96-98; City of Salem v. Purdue Pharma L.P., et al., No. 1984CV01355 (Dkt. #1) at 30-31, 91-93; City of
Springfield v. Purdue Pharma L.P., et al., No. 1984CV01733 (Dkt. #1) at 30-31, 92-93; City of Worcester v. Purdue
Pharma, L.P., et al., No. 1984CV00543 (Dkt. #36); Town of Wakefield v. Purdue Pharma L.P., et al., No. 1984CV01499
(Dkt. #1) at 29-30, 92-93; City of Portsmouth v. Purdue Pharma L.P., et al., No. 740CL19000234-00 (Dkt. #1) at 31-33,
94-95; City of Trenton v. Purdue Pharma L.P., et al., No. MER-L-001167-19 (Trans ID: LCV20191046036) at 36-37,
139-40; City of Norwich v. Purdue Pharma L.P., et al., No. KNL-CV19-6040618-S, Complaint at 33-34, 96-97; Town of
Wethersfield v. Purdue Pharma L.P., et al., No. HHD-CV-19-6112864-S, Complaint at 33-34, 95-97; City of Middletown
v. Purdue Pharma L.P., et al., No. MMX-CV-19-6024949S, Complaint at 33-34, 95-97; and Town of Enfield v. Purdue
Pharma L.P., et al., No. HHD-CV-19-6110751-S, Complaint at 33-34, 96-97.
357 Opposition by the Consortium of Some Massachusetts and Other Municipalities to the Motion for a Preliminary
Injunction In Favor of the Sackler Family Non-Debtors, Purdue Pharma L.P., et al. v. Commonwealth of Massachusetts,
et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al. (Bankr. S.D.N.Y. Oct. 2, 2019)
[https://perma.cc/6Q4G-2YCL].
358 Id. at 2.
359 Id. Nevada counties and municipalities also filed a motion in opposition to the Debtor’s Motion for Preliminary
Injunction containing roughly the same argument as the Municipality Consortium; see Opposition of Nevada Counties
and Municipalities to Motion for Preliminary Injunction, Purdue Pharma L.P., et al. v. Commonwealth of Massachusetts,
et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P. et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Oct.
2, 2019) [https://perma.cc/Z2QG-GFWY].
354
355
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This opposition was buttressed by an opposition filed by governmental entities across the
country (the “Multi-State Governmental Entities Group”) who echoed the Municipality
Consortium’s arguments.360 These plaintiffs argued that they were exercising their police powers
through § 362(b)(4) thereby exempting their actions from the automatic stay.361 The Multi-State
Governmental Entities Group differentiated the Sackler family from the Debtors and argued that
the Sacklers should not be granted preliminary injunction.362 Several other governmental entities
filed objections to Debtors’ preliminary injunction motion.363
In a reply, Debtors argued that the police power exception to the automatic stay does not
limit application of § 105(a) to stay the governmental actions and that courts are empowered to stay
actions not covered by the automatic stay.364 Additionally, the “Ad Hoc Committee” which consists
of (i) ten states, (ii) six political subdivisions of States, and (iii) and a federally recognized American
Indian Tribe filed a statement in support of a limited and conditional stay. 365 The Ad Hoc
Committee pressed that it had negotiated a settlement with the Debtors on behalf of a larger group
of supporting governmental and other claimants. This settlement is threatened if the stay is lifted

360 The Multi-State Governmental Entities Group’s Opposition to Debtors’ Motion for a Preliminary Injunction, Purdue
Pharma L.P., et al. v. Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma
L.P., et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/HU7S-R3QH].
361 Id. at 4.
362 Id. at 6.
363 See, e.g., Limited Objection and Response of Arkansas and Tennessee Public Officials in Opposition to Debtors’
Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v. Commonwealth of Massachusetts, et al., Adv. Pro.
No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019)
[https://perma.cc/Y984-Q7ES]; The States’ Coordinated Opposition to the Debtors’ Motion for Preliminary Injunction
of States’ Law Enforcement Actions Against the Sacklers, Purdue Pharma L.P., et al. v. Commonwealth of
Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD)
(Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/HB2M-KCAM].
364 Plaintiff-Debtors’ Omnibus Reply to Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v.
Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/A4KW-VK3H].
365 The Ad Hoc Committee also included the court-appointed Plaintiffs’ Executive Committee (the “PEC”) in the
federal multi-district litigation captioned In re National Prescription Opiate Litigation, Case No. 17-md-02804, MDL
No. 2804 (N.D. Ohio). Ad Hoc Committee’s Statement in Support of a Limited and Conditional Stay, Purdue Pharma
L.P., et al. v. Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al.,
Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/K56A-R357].
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and the estate exhausted. The Ad Hoc Committee argued that confirming a chapter 11 plan is the
best option to maximize value for all creditors, including the public.366
The OCC filed a statement in support of Debtors’ motion for a preliminary injunction.367
The Committee voiced its support for the temporary injunction as a tool to maximize the estate’s
assets, though it specified that it was not supporting the settlement proposed by the Ad Hoc
Committee.368
On October 11, 2019, the court issued an order pursuant to 11 U.S.C. § 105(a) granting, in
part, the Debtors’ motion for a preliminary injunction.369 The court ordered that the Governmental
Defendants and the Private Defendants are prohibited from—primarily—the commencement or
continuation of their active actions or proceedings against the Debtors (or related parties) that were
or could have been commenced before the commencement of the instant case related to the
Debtors’ prescription opioid business.370 This injunction would last through November 6, 2019.371
This Order was extended on November 6, 2019.372 Notably, some entities were excluded
from this Order’s enjoinment but they opted to abide by its term until December 19, 2019,
including: Arizona, the Ad Hoc Group of Non-Consenting States, and the Multi-State
Governmental Entities Group (the “Potential Opt-Out Parties”).373

Id. at 2.
Official Committee of Unsecured Creditors’ Statement in Support of Debtors’ Motion for a Preliminary Injunction
Pursuant to 1 U.S.C. § 105(a) and Statement in Support of Complaint for Injunctive Relief, Purdue Pharma L.P., et al. v.
Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/JQE4-9F6V].
368 Id. at 1-3.
369 Order Pursuant to 11 U.S.C. § 105(a) Granting, In Part, Motion for a Preliminary Injunction, Purdue Pharma L.P., et
al. v. Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case
No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/YKQ5-8ARQ].
370 Id. at 5.
371 Id. at 4.
372 Second Amended Order, Purdue Pharma L.P., et al. v. Commonwealth of Massachusetts, et al., Adv. Pro. No. 1908289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y. Oct. 3, 2019)
[https://perma.cc/R87Q-USSA].
373 Id. at 5.
366
367
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The Order was extended, again, on November 20, 2019.374 As in the second Order, the
Potential Opt-Out Parties opted to abide by the Order’s injunction.375 This Order allows an OptOut Party to opt out by filing a withdrawal notice with the court on either December 19, 2019 or
February 21, 2020.376 If done, the exiting parties will then be bound by the same terms imposed on
other parties by the November 6 order until April 8, 2020.377
The Order was again extended on December 9, 2019.378 Here, the same terms of the
injunction apply and the Potential Opt-Out Parties agreed to abide by the terms of the second Order
granting preliminary injunction.379 The order was again extended on December 9, 2019.380 Here, the
same terms of the injunction apply, and the Potential Opt-Out Parties agreed to abide by the terms
of the second order granting preliminary injunction.381 The order was extended, in the same terms,
several times—the most recent being on March 26, 2021. 382

374

Third Amended Order Granting Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v. Commonwealth of
Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD) (Bankr.
S.D.N.Y. Oct. 3, 2019) [https://perma.cc/93R3-RA4Z].
375 Id. at 5.
376 Id. at 6.
377 Id.
378 Fourth Amended Order Granting Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v. Commonwealth
of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD)
(Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/4T6S-2Z6R].
379 Id. at 6.
380 Fourth Amended Order Granting Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v. Commonwealth
of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 19-23649 (RDD)
(Bankr. S.D.N.Y. Oct. 3, 2019) [https://perma.cc/4T6S-2Z6R].
381 Id. at 6.
382 Sixteenth Amended Order Granting Motion for a Preliminary Injunction, Purdue Pharma L.P., et al. v.
Commonwealth of Massachusetts, et al., Adv. Pro. No. 19-08289 (RDD), In re Purdue Pharma L.P., et al., Case No. 1923649 (RDD) (Bankr. S.D.N.Y. Mar. 26, 2021) https://perma.cc/DK3T-9D38.
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State of Arizona v. Richard Sackler et al., No. 22O151
On July 31, 2019, the State of Arizona through its Attorney General Mark Broncivh filed an
action against Purdue Pharma L.P. and the Sackler family383 in the original jurisdiction of the United
States Supreme Court.384 Arizona claimed that the Court had original jurisdiction over the action
under Article III, § 2, cl. 2 of the U.S. Constitution because it is a dispute in which “a State [is a]
Party.”385
In its petition, Arizona asserted claims under its fraudulent transfer laws against Debtors’
and the above named Sackler’s.386 Arizona alleged that the Sackler family unlawfully transferred
billions of dollars out of their company to avoid liability.387 Eventually, though, the Court declined
to hear the case.388

Including Richard Sackler, Theresa Sackler, Kathe Sackler, Jonathan Sackler, Mortimer D.A. Sackler, Beverly Sackler,
David Sackler, and Ilene Sackler Lefcourt. https://perma.cc/2DKG-L3BJ
384
Plaintiff’s Motion for Leave to File Bill of Complaint, State of Arizona v. Richard Sackler, et al., No. 22O151 (Aug. 6,
2019), Id.
385 Id. at 5.
386 Id. at 4-5.
387 Id.
388 Tucker Higgins, Supreme Court refuses to hear unusual case brought by Arizona against Purdue Pharma’s Sacklers over the opioid
epidemic, CNBC (last updated Dec. 10, 2019), https://www.cnbc.com/2019/12/09/opioid-crisis-supreme-court-refusesto-hear-case-against-purdues-sacklers.html [https://perma.cc/7ELZ-4KCW].
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Executory Contracts
Section 365(a) of the Bankruptcy Code provides that a debtor in possession, subject to the
court’s approval, may assume or reject any executory contract or unexpired lease.389 Despite being
financially healthy, apart from the mass tort litigation exposure, the Debtors still took advantage of
the reorganization to reject leases it deemed burdensome or redundant and manage executory
contracts for the benefits of its estate, as described below.
The Coventry Facility
Rhodes Technologies (a subsidiary of Purdue Pharma L.P.), owned and operated an active
pharmaceutical Ingredient (“API”) manufacturing facility in Coventry, Rhode Island (the “Coventry
Facility”) which manufactured APIs used by Purdue Pharma L.P.390 The facility originally
manufactured oxycodone API for OxyContin, but the Debtors opted to outsource its API supply
needs away from the Coventry Facility.391
To avoid the costs associated with shutting down the plant, the Debtors conducted an extensive
marketing and negotiation process to sell the plant.392 Following a thorough search and competitive
bidding process, Noramco Coventry LLC was selected as the purchaser (“Noramco”).393 As a
condition to closing, the Debtors and Noramco agreed to enter into a supply agreement, for a
minimum term of seven years, with two two-year renewals at the Debtors’ option.394

11 U.S.C. § 365(a) https://perma.cc/GU7L-LJDJ.
Notice of Hearing on Motion of the Debtors for an Order (I) Approving Sale of Debtors’ Coventry Facility and
Related Assets Free and Clear of Liens, Claims, Interests and Encumbrances, (II) Approving Debtors’ Entry Into a
Long-Term API Supply Agreement, (III) Authorizing Assumption and Assignment or Assignment, as Applicable, of
Executory Contracts and Unexpired Leases and (IV) Granting Related Relief, In re Purdue Pharma L.P., et al., Case No.
19-19-23649 (Bankr. S.D.N.Y. Nov. 5, 2019), https://perma.cc/7WVA-6ZDT.
391 Id. at 4.
392 Id.
393 Id.
394 Id. at 8.
389
390
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In connection with this sale, the Debtors sought authorization to assume and assign or assign, as
applicable, all contracts or leases associated with the Coventry Facility (the “Assigned Contracts”)395
to the purchaser per § 365(b).396 The Assigned Contracts included all service contracts, supply
agreements, and leases related to the Coventry Facility. Though Bankruptcy Rule 6006(f)(6) limits
omnibus motions to assume or reject multiple executory contracts to one hundred, the Debtors
argued that that should not apply here.397 The Debtors cited, among other reasons, judicial efficiency
as reason to waive this limit.398
No objections to the motion were filed, and an order was entered authorizing the Debtors to
enter the sale, enter the long-term API supply agreement, and authorize assumption and assignment
or assignment of the Assigned Contracts.399

Supra note 27, Exhibit B, pp. 321-24.
Id. at 15.
397 Id. 32-33.
398 Id. at 33.
399 Order (I) Approving Sale of Debtors’ Coventry Facility and Related Assets Free and Clear of Liens, Claims, Interests,
and Encumbrances, (II) Approving Debtors’ Entry into a Long-Term API Supply Agreement, (III) Authorizing
Assumption and Assignment or Assignment, as Applicable, of Executory Contracts and Unexpired Leases and (IV)
Granting Related Relief, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Oct. 1, 2020),
https://perma.cc/QJ39-23FV.
395
396
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Unexpired Leases
Deadline to Assume or Reject Unexpired Leases of Nonresidential Real Property
On December 5, 2019, the Debtors filed a motion to extend the deadline to assume or reject
unexpired leases of nonresidential real property from January 13, 2020 to April 13, 2020.400 In the
motion, the Debtors disclosed its unexpired leases, specifically: the Wrap Lease, the Aviro Health
L.P. lease , a lease of administrative office space in Coventry, Rhode Island, and leases of offices in
Washington, D.C. and Warren, Rhode Island that are utilized by certain of the Debtors’ employees
from time to time. 401 The Debtors stated that they were still evaluating the leases to determine
which, if any, are burdensome or unnecessary and that it would be premature, at this time, to assume
or reject any unexpired leases.402 The Debtors claimed that any extension would not prejudice the
lessors that are parties to their unexpired leases because they expect to perform all undisputed
obligations arising from and after their petition date in a timely fashion, as required by § 365(d)(3).403
An order granting this extension was entered on December 20, 2020.404

400 Debtors’ Motion For Entry of an Order Extending the Deadline to Assume or Reject Unexpired Leases of
Nonresidential Real Property, In re Purdue Pharma L.P., et al., Case No. 19-19-23649, 5 (Bankr. S.D.N.Y. Dec. 5, 2019),
https://perma.cc/2MSC-5JNU.
401 Id.
402 Id. 4-5.
403 Id. at 5. See also 11 U.S.C. § 365(d)(3), https://perma.cc/UWY8-9ADW.
404 Order Extending the Deadline to Assume or Reject Unexpired Leases of Nonresidential property, In re Purdue
Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Dec. 20, 2019), https://perma.cc/ZT36-JRJT.
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Princeton Lease
The Debtors sought permission to reject a certain lease, effective September 26, 2019, dated
Mach 15, 2017, by and between itself and Princeton Center Office, LLC (the “Princeton Lease”).405
The Debtors stated that due to staffing reductions, it had physically vacated the premises and, in its
business judgment, no longer had need for the premises or its accompanying lease.
No objections to the motion were filed, and an order authorizing the Debtors to reject the
Princeton lease was entered shortly after.406

Motion of Debtors for Entry of an Order (I) Authorizing the Rejection of Commercial Lease and (II) Granting
Related Relief, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Sept. 14, 2020),
https://perma.cc/FCZ7-GMRN.
406 Order Granting Motion (I) Authorizing the Rejection of Princeton Lease and (II) Granting Related Relief (Setting
Bar Date for Rejection Claim), In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Nov. 21, 2019),
https://perma.cc/2Y4D-HLUF.
405

83

Headquarters Lease
The Debtors’ corporate headquarters is located at One Stamford Forum at 201 Tresser Blvd,
Stamford, CT 06901 (“One Stamford Forum”).407 One Stamford Forum is owned by One Stamford
Realty L.P. (“OSR”), which is owned by the Debtors’ existing shareholders.408 Debtor is the tenant
under a certain lease, dated April 6, 2006, between Purdue Pharma L.P. (“PPLP”) and OSR (the
“Existing PPLP Lease”).409 Debtors also has various subtenants in the building.410 Debtors are also
the tenant under a lease dated December 18, 2015 (the “Headquarters Wrap Lease”) with OSR as
landlord.411
The Debtors sought permission to (1) reject the Headquarters Wrap Lease, effective the same
date the 2021 Headquarters Lease (defined below) becomes effective; (2) enter into a replacement
lease with OSR and PPLP (the “2021 Headquarters Lease”); (3) assume (a) the Existing PPLP Lease
and (b) a certain sublease, dated August 10, 2009, between the Debtors and UBS AG (the “Existing
UBS Sublease”); and (4) enter into a surrender agreement between the Debtors and Pharmaceutical
Research Associates (the “Surrender Agreement”).412
The Debtors point to a consistent reduction in its employees (67% employee reduction) as its
primary motivation for rejecting the Headquarters Wrap Lease.413 Given their staffing reductions,
the Debtors no longer need the office space it negotiated for when the lease was signed in 2015.414

Id. at 4.
Id.
409 Id. at 3.
410 Id. at 4.
411 Id.
412 Notice of Hearing on Motion of Debtors for Entry of an Order (I) Authorizing the Rejection of Commercial Lease,
(II) Authorizing Entry Into New Headquarters Lease, (III) Authorizing the Assumption of Commercial Leases, and (IV)
Granting Related Relief, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Jan. 31, 2020) 3,
https://perma.cc/5U8M-6V5T.
413 Id. at 5.
414 Id.
407
408
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Additionally, the Debtors contend that subleasing the excessive office space would not be
economical when compared to simply rejecting the lease.415
At the same time, as a replacement for the Headquarters Wrap Lease, the Debtors sought
permission to enter the 2021 Headquarters Lease, specifically to let the ninth and tenth floors of
One Stamford Forum.416 The total cost for the new lease would be $16.7 million, for a term of three
years, for only the ninth and tenth floors of the building.417 The Debtors, at the time, sublet a
portion of the ninth floor of One Stamford Forum to Pharmaceutical Research Associates L.P.
(“PRA”), a director shareholder (the “PRA Sublease”). To enable the Debtors to fill out the entire
ninth floor for the Headquarters Wrap Lease, the Debtors and PRA entered into a Surrender
Agreement, in which PRA agreed to relinquish its rights under the PRA Sublease and vacate the
subleased premises as of July 31, 2020.418
Additionally, the Debtors sought to maintain the status quo through the end of 2020 by
assuming the Existing PPLP lease and the UBS Sublease.419 No cure costs would be incurred by the
assumption of these leases as the Debtors were current on all their obligations under them.420
In response to this petition, the OCC expressed concern that this motion presupposes that a
“public trust” model of corporate governance will emerge from the bankruptcy; but took no issue
with the motion.421 Shortly after, the court granted the motion.422

Id.
Id. at 6.
417 Id.
418 Id. at 7.
419 Id. 7-8.
420 Id.
421 Statement of the Official Committee of Unsecured Creditors With Respect to the Motion of Debtors for Entry of an
Order (I) Authorizing the Rejection of Commercial Lease, (II) Authorizing Entry Into New Headquarters Lease, (III)
Authorizing the Assumption of Commercial Leases and (IV) Granting Related Relief, In re Purdue Pharma L.P., et al.,
Case No. 19-19-23649 (Bankr. S.D.N.Y. Feb. 17, 2020), https://perma.cc/TBM8-3FNX.
422 Order (I) Authorizing the Rejection of Commercial Lease, (II) Authorizing Entry Into New Headquarters Lease, and
(III) Granting Related Relief, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Feb. 24, 2020),
https://perma.cc/A8KG-URC6.
415
416
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The Aviro Lease
The Debtors sought permission to assume a lease, dated May 28, 2019, between 65 W 36 LLC
(the “Aviro Lessor”) and Aviro Health L.P. (“Aviro”); and to extend the current § 365(b)(4) deadline
with respect to certain extended deadlines leases (with the written consent of the lessors).423 Aviro is
a wholly owned subsidiary of Purdue Pharma L.P. that engages in the marketing, sale, and
distribution of over-the-counter products in the U.S.; Aviro maintains offices at 65 West 36th Street,
New York, N.Y. 10018.424 The Debtors determined $26,216.13 is the amount necessary to cure the
Aviro Lease.
The Debtors are also lessees of various unexpired leases of nonresidential real property and
believed that it is in the best interest of the estate to extend the § 365(d)(4) deadline.425 The Debtors
feared that, absent an extension, they would be forced to make less than fully informed decisions
regarding the assumption or rejection of its nonresidential real property to the detriment of its
estate.426 The Debtors obtained written permission from its lessors to extend this deadline.427
No objections were filed to this motion and an order granting the relief requested was entered
shortly after.428

Motion of Debtors for Entry of an Order (I) Authorizing the Assumption of a Certain Unexpired Lease and (II)
Further Extending the Debtors’ Deadline to Assume or Reject Certain Unexpired Leases with the prior Written Consent
of the Lessors, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Mar. 4, 2020),
https://perma.cc/KK2D-6E62.
424 Id. at 4.
425 Id. at 5.
426 Id. at 5-6.
427 Id.
428 Order (I) Authorizing the Assumption of a Certain Unexpired Lease and (II) Further Extending the Debtors’
Deadline to Assume or Reject Certain Unexpired Leases with the Prior Written Consent of the Lessors Under Such
Leases, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Mar. 18, 2020),
https://perma.cc/FT8Y-5JGE.
423
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Proposed Compensation Plans
The Debtors attended three separate hearings regarding their modified employee compensation
programs including the 2019 Annual Incentive Plan implemented prior to the Chapter 11 petition,
payments under the Debtors Long-Term Results Plan (the “LTRP”) due in 2020, and the Debtors’
Existing Non-Executive Retention Plan (collectively, the “2019 Payments”).429 The Debtors sought
permission to maintain their historical compensation practices, adjusted to meet their current
circumstances. The proposals (the “Proposed Compensation Plans”) sought to continue
motivation, engagement, and retention of the workforce they deemed indispensable and thereby
maximize the value of their estate.430 The Proposed Compensation Plans contained two
components:
Key Employee Incentive Plan (“KEIP”)
This plan would apply to the Debtors’ eight current insider employees: (1) the CEO, (2) the
CFO, (3) the General Counsel, (4) Senior Vice President, Intellectual Property Law & Public Health
Initiatives, (5) Chief Technical Operations Officer, (6) President, Imbrium Therapeutics, (7)
President, Rhodes Pharmaceuticals, and (8) President, Rhodes Technologies.431 The Debtor’s

429 Debtors’ Motion for Entry of an Order Authorizing Implementation of a Key Employee Incentive Plan and a Key
Employee Retention Plan, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Sept. 9, 2020),
https://perma.cc/CV8M-U8RY. The 2019 Payments were approved in a combination of the following orders: the Final
Order Granting Motion Authorizing (1) Debtors to (A)Pay Prepetition Wages, Salaries, Employee Benefits and Other
Compensation and (B)Maintain Employee Benefits Programs and Pay Related Administrative Obligations, (II)
Employees and Retirees to Proceed with Outstanding Workers’ Compensation Claims and (III) Financial Institutions to
Honor and Process Related Checks and Transfers; Supplemental Final Order Authorizing (I) Debtors to (A) Pay
Prepetition Wages, Salaries, Employee Benefits and Other Compensation and (B) Maintain Employee Benefits Programs
and Pay Related Administrative Obligations, (II) Employees and Retirees to Proceed with Outstanding Workers’
Compensation Claims and; (III) Financial Institutions to Honor and Process Related Checks and Transfers; and the
Second Supplemental Final Order Authorizing (I) Debtors to (a) Pay Certain Prepetition Wages, Salaries, Employee
Benefits and Other Compensation and (b) Maintain Employee Benefits Programs and Pay Related Administrative
obligations, (ii) Employees and Retirees to Proceed with Outstanding Workers Compensation Claims and (iii) Financial
Institutions to Honor and Process Related Checks and Transfers.
430 Id. at 8.
431 Id. at 10.
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claimed that this senior management is essential to guiding it through their reorganization and
maximizing the value of its estate.432
Payments under KEIP are contingent on the Debtors’ achievement of certain performance
metrics and institute a floor and ceiling for amounts, depending on the employees’ performance with
respect to those metrics.433 The KEIP range is laid out below:434
KEIP Participant
CEO
CFO
General Counsel and
Corporate Secretary
Senior VP, Intellectual
Property Law & Public Health
Initiatives
Chief Technical Operations
Officer
President, Imbrium
Therapeutics
President, Rhodes
Pharmaceuticals
President, Rhodes
Technologies
Total

Payout Range = 75% to 100%
Threshold KEIP Award
Target KEIP Award
$2,640,000
$3,520,000
$750,000
$2,619,000
$1,964,000
$2,619,000
$508,000

$678,000

$519,000

$691,000

$468,000

$624,000

$279,000

$372,000

$272,000

$362,000

$7,400,000

$9,866,000

Key Employee Retention Plan (“KERP”)
The Debtors sought to reward their KERP eligible employees for their efforts leading up to and
during the reorganization. The Debtors pointed out that, using the same criteria used previously to

Id.
Id. at 11.
434 Id. 11-12.
432
433
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determine whether KEIP participants were insiders,435 no KERP participant was an insider.436 The
participants are approximately 614 employees, seventeen (17) of which are Vice Presidents, while the
remainder are middle management and professional employees such as scientific research and
regulatory and compliance personnel.437
The KERP program is not subject to performance criteria like KEIP, as the KERP goal was
retain its participants given their challenging working conditions.438 The KERP award was to be
paid out in two installments, in October 2020 and January 2021, with certain criteria designed to
ensure employee retention.439 The total aggregate target (and maximum) payment under the KERP
Award is approximately $21,600,000.440
The Committee of Accountability filed a motion in opposition to the Debtors’ motion for
implementation of KEIP and KERP.441 In its brief argument, the Committee of Accountability
took issue with the Debtors’ rationale for the bonuses: that Purdue Pharma L.P. (as an entity)—and
thereby its employees—“is an asset in the fight against the opioid crisis.”442 The Committee of
Accountability argued that the company has been an obstacle to its victims’ recovery and that the
money should instead be directed towards their recovery.443

435 The Company categorized an employee as an insider if the employee met any one of the following five criteria. The
employee: (1) is an officer appointed by the Board; (2) holds the title of Chief Executive Officer, Chief Financial Officer,
Chief Operating Officer, General Counsel or Senior Vice President; (3) reports to the Board; (4) has authority to make
Company-wide or strategic decisions, including critical financial decisions; or (5) is in a position to determine his or her
own compensation. Notably, no insider employee of the Debtors is in a position to determine his or her own
compensation, which is the responsibility of the Compensation Committee and the Board. Id. at 23-24.
436 Supra note 81, at 23.
437 Id.
438 Id. at 25.
439 Id.
440 Id.
441 Memorandum of Law in Support of Ad Hoc Committee on Accountability’s Objection to Debtor’s Motion to Pay
Bonuses, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Sept. 22, 2020),
https://perma.cc/ZDG6-LU9C.
442 Id. at 1; quoting supra note 81.
443 Id. at 1-2.
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On October 1, 2020, the court entered an order authorizing the debtors to implement
KERP as proposed while a hearing for KEIP was set for later that month.444 On September 22,
2020, the U.S. Trustee and the Ad Hoc Committee on Accountability filed objections to the motion,
arguing chiefly that 503(c) prohibits insider transfers unless “necessary [to] preserv[e] the estate”
which, they argued, the Debtors failed to show.445
On October 1, 2020, the court entered an order authorizing the Debtors to implement
KERP.446 On October 28, 2020, the court entered the Order Authorizing the Debtors to
Implement a Key Employee Incentive Plan, which granted the Debtors authority to implement
KEIP modified with respect to (i) General Counsel; (ii)Chief Technical Operations Officer; (iii)
President, Rhodes Pharmaceuticals; and (iv) President, Rhodes Technologies.447 On November 17,
2020, the court entered the Supplemental Order Authorizing the Debtors to Implement a Key
Employee Incentive Plan, which granted the Debtors authority to implement the KEIP modified
with respect to the CEO and CFO.448

Order Authorizing the Debtors to Implement a Key Employee Retention Plan, In re Purdue Pharma L.P., et al., Case
No. 19-19-23649 (Bankr. S.D.N.Y. Oct. 1, 2020), https://perma.cc/VYV3-WFPL.
445 Objection of the United States Trustee to Motion of Debtors for Order Authorizing Implementation of a Key
Employee Incentive Plan and a Key Employee Retention Plan, In re Purdue Pharma L.P., et al., Case No. 19-19-23649
(Bankr. S.D.N.Y. Sep. 22, 2020), https://perma.cc/PG4Y-6WEX; see also Memorandum of Law In Support of Ad Hoc
Committee on Accountability’ Objection to Debtors’ Motion to Pay Bonuses, In re Purdue Pharma L.P., et al., Case No.
19-19-23649 (Bankr. S.D.N.Y. Sept.22, 2020), https://perma.cc/NZB3-2A9S.
446 Order Authorizing the Debtors to Implement a Key Employee Retention Plan, In re Purdue Pharma L.P., et al., Case
No. 19-19-23649 (Bankr. S.D.N.Y. Oct. 1, 2020), https://perma.cc/8NWN-GPP6.
447 Order Authoring the Debtors to Implement a Key Employee Incentive Plan, In re Purdue Pharma L.P., et al., Case
No. 19-19-23649 (Bankr. S.D.N.Y. Oct. 8, 2020), https://perma.cc/8Q7S-3RAZ.
448 Supplemental Order Authorizing the Debtors to Implement a Key Employee Incentive Plan, In re Purdue Pharma
L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Nov. 18, 2020),https://perma.cc/3J29-DN9V.
444
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Extension Period
§ 1121(b) provides for a period of 120 days after the commencement of a chapter 11 case
during which time a debtor has the exclusive right to file a plan of reorganization (the “Exclusive
Filing Period”). Additionally, § 1121(c)(3) provides that if a debtor files that plan within the
Exclusive Filing Period, it shall have a period of 180 days after the petition date to obtain acceptance
of such plan (the “Exclusive Solicitation Period”, collectively the “Exclusivity Periods”).449
The Debtors’ Exclusive Filing Period and Exclusive Solicitation Period originally was set to
expire on January 13, 2020 and March 13, 2020, respectively.450 The Debtors filed multiple motions
to extend the Exclusivity Periods, with the Exclusive Solicitation Period ultimately being extended to
May 17, 2021451 and the Exclusive Filing Period ultimately being extended to March 15, 2021.452

Plan Disclosure Statement at 51.
Id.
451 Third Extension Order, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Dec. 16, 2020),
https://perma.cc/5FKW-7PN8.
452 Fifth Extension Order, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Mar. 1, 2021),
https://perma.cc/PVW7-BHWX; see also Plan Disclosure Statement at 51.
449
450
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Mediation
Though the Debtors sought to create an efficient method of adjudication of its claimants
through this bankruptcy, it discovered that the various creditor groups had vastly different views on
the various claims asserted as well as how value from the estate should be allocated between groups.
This conflict prompted the Debtors to negotiate for mediation to navigate the resource allocation
conflict. As such, on February 20, 2020, the Debtors filed a motion seeking an order appointing
mediators.453 The Debtors identified three broad class of claimants that would vie for resources: (1)
the federal government, (2) non-federal public claimants, and (3) private parties.454
Prior to filing, the Debtors were able to receive consent form many of the affected groups,
including: the OCC, the Ad Hoc Group, the Non-Consenting States; the Multi-State Governmental
Entities Group, the NAS Babies, and the Ad Hoc Group of Hospitals, the Ad Hoc Group of
Individual Victims, and various insurance purchasers.455
An order granting this motion was entered shortly after the motion was filed.456 The order
affirmed that no party was to be bound by the mediation unless it agreed to be bound.457
On March 23, 2021, the mediators issued their report disclosing the extent to which the
mediation was successful.458 The mediators stated that the mediation’s primary purpose—reaching a
consensual agreement as to the estate allocation between and among the public and private creditor
groups—was successfully achieved.459

453 Debtors’ Motion for Entry of an Order Appointing Mediators, In re Purdue Pharma L.P., et al., Case No. 19-1923649 (Bankr. S.D.N.Y. Feb. 20, 2020, https://perma.cc/TQW3-ZBLD.
454 Id. at 7.
455 Id. at 5.
456 Order Appointing Mediators, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Mar. 4, 2020),
https://perma.cc/E9MM-GPNF.
457 Id. at 7.
458 Mediators’ Report, In re Purdue Pharma L.P., et al., Case No. 19-19-23649 (Bankr. S.D.N.Y. Mar. 23, 2021),
https://perma.cc/ADZ3-86VS.
459 Id. at 8.
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Chapter 11 Plan
Purdue Pharma submitted its plan of reorganization on March 15, 2021.460 The ostensible
goal is of the plan is to turn over all of the Debtors’ assets “for the benefit of the claimants and the
American public, with the goal of directing as much of the value of their assets as possible to
combatting the opioid crisis in this country.”461 Despite this benevolent goal statement, the real goal
of the plan appears to be to use Chapter 11 bankruptcy to consolidate litigation and impose a
settlement agreement that will allow Purdue’s shareholders (primarily the Sackler family) to walk
away from the company in exchange for the company’s assets and a large cash payment. Before
filing Purdue’s petition and after multiple rounds of mediation, the Sackler family and a critical mass
of plaintiffs agreed on the following general settlement framework: “(1) Purdue Pharma’s existing
shareholders would relinquish all of their equity interests in the Debtors and consent to the transfer
of all of the Debtors’ assets to a trust or similar post-emergence structure for the benefit of
claimants and the U.S. public, ‘free and clear’ of liabilities to the fullest extent permitted by law; (2)
Purdue Pharma’s existing shareholders would engage in a sale process for their ex-U.S.
pharmaceutical companies; and (3) Purdue Pharma’s existing shareholders would contribute at least
an additional $3 billion over seven years (in addition to 100% of the value of all 24 Debtors), with
the hope of substantial further contemplated contributions from the sales of their ex-U.S.
pharmaceutical businesses.”462

Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors, In re Purdue Pharma L.P.,
No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019),[hereinafter “Chapter 11 Plan”], https://perma.cc/2U2VNHJL.
461 Disclosure Statement for Chapter 11 Plan for Purdue Pharma L.P. and its Affiliated Debtors, In re Purdue Pharma L.P.,
No. 19-23649 (Bankruptcy S.D.N.Y. filed Sept. 15, 2019), [hereinafter “Disclosure Statement”],
https://perma.cc/N48Y-RPLJ.
462 Id. at 3.
460
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While Purdue’s mediation with its civil plaintiff creditors was ongoing, Purdue entered into a
criminal plea agreement with the United States Department of Justice, as well as a civil settlement
agreement with the United States.463 Purdue pleaded guilty to one count of conspiring to defraud the
United States and to violate the Food, Drug, and Cosmetic Act, and two counts of conspiracy to
violate the Federal Anti-Kickback Statute.464 This plea was entered in the United States District
Court for the District of New Jersey on November 24, 2020.465 The New Jersey District Court will
consider the plea agreement at a sentencing hearing that will take place after confirmation of
Purdue’s chapter 11 plan.466 As part of this plea agreement Purdue and the United States agreed to a
$2 billion criminal forfeiture judgment with the status of an allowed super priority administrative
claim expense.467 This judgment will not be entered until after the plan has been confirmed and the
New Jersey District Court has approved of the settlement agreement.468 Importantly, the United
States has agreed to allow Purdue a credit offsetting this judgment for up to $1.775 billion if at least
this amount in value is distributed to claims asserted by state, tribal, or local governmental entities
and the plan provides for the creation of a public benefit company (among other terms).469 The
DOJ’s civil claim against Purdue was settled by a $225 million payment by the Sackler family.470
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Sackler Family
One of the major goals behind Purdue’s bankruptcy is to obtain third-party releases for its
beneficial owners, the Sackler family, in exchange for cash payments and all of Purdue’s assets and
interests. Essentially, the goal is for the Sackler’s to give up the company and billions in cash in
exchange for the chance to wash their hands of the opioid crisis they are largely responsible for
creating, with the backing of United States law. Notably, the Sacklers are also trying to protect their
remaining wealth, which Forbes estimated to be worth $13 billion in 2015.471 Under the plan as
proposed, the Sackler family’s cash contribution is $4.5 billion, an increase from the $3.0 billion
figure initially negotiated with plaintiffs.472 Whether this will be enough to get the Sackler family their
coveted releases will depend on both the acceptance of the plan by Purdue’s creditors, and the
willingness of the court to grant releases to non-debtor parties.
Third-party releases are controversial and “arise where a debtor attempts to extend releases
to certain affiliated non-debtor parties whose participation in or impact on the chapter 11 process
will allegedly affect the debtor’s ability to reorganize.”473 Section 524(e) of the bankruptcy code
provides that “discharge of a debt of the debtor does not affect the liability of any other entity . . .
on such debt.”474 This seems to provide an outright prohibition on third-party releases of the type
that the Sackler family is pursuing through this reorganization. Despite this seemingly clear language,
the Second, Third, Fourth, Sixth, and Eleventh Circuits all hold that §524 does not limit the
bankruptcy court’s broad §105 powers to “issue any order, process, or judgment that is necessary or
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appropriate to carry out the provisions of this title.”475 Importantly, Purdue’s case is in the Southern
District of New York, which sits in the Second Circuit. This means that the court may grant thirdparty releases to the Sackler family. Proponents of third-party releases, and the Debtors’ attorneys,
will likely argue that granting these releases is the only way to get the Sacklers to make any
contribution, and will end up creating more value overall for the creditors. Opponents will likely
argue that third-party releases are inequitable on these facts given the Sackler family’s role in creating
the devastating opioid crisis, that the Sacklers should be required to contribute more in light of their
high net worth earned almost entirely through Purdue,476 or that §524(e) simply prohibits the court
from granting this type of release.
The potential for third-party releases in this case has generated public outrage.477 U.S.
legislators even introduced a bill to amend §105(b) to provide that “A court may not — . . . except
as provided by section 524(g) of this title, enjoin or release a claim against a non-debtor by a State,
municipality, federally recognized tribe, or the United States.”478 The lawmakers proposing the bill
apparently found the specifically targeted language to be too subtle for their tastes and named the
act the SACKLER Act, (short for “Stop Shielding Assets from Corporate Known Liability by
Eliminating Non-Debtor Releases Act”), in order to avoid any confusion about the purpose of the
proposed amendment.479 Purdue’s plan in its current form would provide third-party releases to the
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Sackler family in exchange for Purdue itself and $4.5 billion. Whether public and congressional
outrage affects the plan’s confirmation has yet to be determined.
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Means for Implementation
One of the main features of Purdue’s chapter 11 plan is the creation of “NewCo”, a newly
formed Delaware LLC.480 The Debtors’ will transfer substantially all of their non-cash assets to
NewCo along with $200 million of cash.481 The only non-cash assets that will not be transferred to
NewCo are certain causes of action and insurance rights.482 NewCo will use the cash and non-cash
assets to operate a business and in order to ensure this is done in a responsible and sustainable
manner it will be required to balance: “(i) the interests of its stakeholders to fund and provide
abatement of the opioid crisis; (ii) effective deployment of its assets to address the opioid crisis; and
(iii) the interests of those materially affected by its conduct.”483 The plan provides that the net value
generated by NewCo will be put towards mitigating the opiate crisis that was created in large part by
the Debtors.484 NewCo will also guarantee the Master Disbursement Trust discussed below.485
NewCo is a manager-managed LLC, so NewCo will be controlled by managers, rather than a
board of directors.486 The selection of managers will involve lots of input from interested parties, an
understandable proposition considering the importance of NewCo to the Debtors’ plan and the
worry that NewCo could engage in the same types of harmful business practices that landed the
Debtors’ in this reorganization to begin with. NewCo will have seven managers, who must each
have experience in one or more of the following areas: pharmaceuticals, public policy (including
public health policy), law enforcement, ethics and compliance, finance, audit, general business
and/or corporate governance issues.487The managers will initially be selected by the Ad Hoc
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Committee but must be accepted by the Multi-State Governmental Entities Group.488 The OCC, as
well as Purdue itself, will be consulted regarding the appointment of managers.489 Finally, the DOJ
will have the right to observe this selection process.490 The plan requires that NewCo’s managers be
disinterested and independent.491 Importantly, the Sackler family will have no involvement in any
aspect of NewCo’s governance, operations, or the selection of NewCo’s managers.492
NewCo will have one member, TopCo. TopCo will also be a newly formed managermanaged Delaware LLC.493 As NewCo’s sole member, TopCo will own all of the voting rights and
equity in NewCo.494 TopCo will distribute its excess cash to the National Opoid Abatement Trust
(“NOAT”) and the Tribe Trust, TopCo’s two members.495 TopCo will be controlled by three
disinterested managers selected by the same process as NewCo’s managers.496 This management
should provide another layer of oversight to ensure that NewCo fulfills its public benefit goals and
prevent malfeasance. In the event that NewCo’s initial managers must be replaced, the managers of
TopCo will choose the replacements.497

Trusts
Implementation of the plan also includes the creation of numerous trusts. The National
Opioid Abatement Trust is a newly formed statutory trust that will hold all of the voting interest in
TopCo, and a majority of the economic interest in TopCo.498 It will receive settlement payments for
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the benefit of non-federal domestic governmental claimants and assume liability for administering
these claims.499 This trust will be funded with approximately $4 billion in cash payments over time
including distributions of excess cash from TopCo and the Master Disbursement Trust.500 Under the
proposed plan it would be governed by creditor trustees selected by the Ad Hoc Committee in
consultation with the Debtors.501
A Tribe Trust will also be created to collect and distribute payments to native American tribe
groups and assume all liability for native American tribe claims.502 The tribe trust will hold the
minority economic interest in TopCo not held by the NOAT and hold the interest of a residual
beneficiary in the Master Disbursement Trust.503 This trust will initially be funded with $50 million
but is expected to be funded with a total of $141 million over time.504 This trust will be governed by
trustees chosen by the native American tribe group with the consent of the Debtors.505 It is
interesting to note that the estimated total recovery for native American groups proposed under the
plan (which may be higher than the number actually received) pales in comparison to the total
amount of professional fees generated in this reorganization.
The Master Disbursement Trust is another key trust created pursuant to the chapter 11 plan.
The main function of this trust will be to receive settlement payments and distribute them to various
private creditor trusts.506 It will also hold the right to receive agreed settlement payments from the
Sacklers and the ability to enforce these rights if necessary.507 Additionally, it will seek recovery
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under certain of the Debtors’ insurance policies and pay the proceeds to various creditor trusts.508
Under the plan, the trust would be governed by three trustees.509 These trustees would be selected by
the Ad Hoc committee and accepted by the Multi-State Governmental Rntity Group.510 The
Debtors would be consulted regarding the appointments and the DOJ would have the right to
approve the process.511 Finally, these trustees will select an executive director to carry out the trusts
day to day operations.512 Like every other aspect of this plan, the trust involves multiple levels of
governance and oversight, ostensibly to prevent malfeasance, but undeniably a generator of even
more professional fees and costs to the bankruptcy estate.
The private creditor trusts that will hold beneficial interests in and receive distributions from
the Master Disbursement Trust include the Personal Injury Trust, the Hospital Trust, the Third
Party Payor Trust, and the NAS Monitoring Trust.513 The Hospital Claims trust is established for the
benefits of hospital claimants and will be funded with $250 million.514 The Third Party Payer Trust
will be established for the benefit of claimants that reimburse and manage healthcare expenses and
will be funded with $365 million.515 The NAS Monitoring Trust is established for the benefit of
holders of claims against Purdue on behalf of children who have been diagnosed with medical,
physical, cognitive, or emotional conditions resulting from intrauterine exposure to opioids or
opioid addiction treatment medications.516 The NAS Monitoring Trust will be funded with $60
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million.517 The Personal Injury Trust is established for the benefit of personal injury claimants and
will be funded with $700 million to $750 million.518
Not to be forgotten, the plan also provides a vehicle for payments to professionals through
the Plan Administration Trust.519 This trust will maintain the professional fee escrow account.520 The
funding for this trust will be determined based upon need.
The plan also provides for some creditor payments to be made without using trusts. The
Debtors’ will make a $6.5 million truth initiative contribution for the benefit of ratepayer
claimants.521An additional $15 million will be set aside for general unsecured claim cash.522

Classification and Treatment of Claims and Interests
Under §1126(f) each holder of a claim or interest of a class that is not impaired by a plan is
conclusively presumed to have accepted the plan and the debtor is not required to solicit
acceptances from these classes of creditors.523 A class is impaired if the plan alters a party’s legal,
equitable, or contractual rights.524 Under Purdue’s proposed plan, its secured creditors and other
priority creditors are to receive payment in full in cash or other treatment that renders their claims
unimpaired (such as reinstatement of secured claims under §1124).525 The class of “other priority
creditors” consists of claims entitled to priority under §507(a), which include wages and
commissions earned by individuals within the 180 days immediately preceding the filing of the
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petition and a variety of other claims.526 The general unsecured claims of Aldon Therapeutics L.P.
and Avrio Health L.P. are also proposed to receive full cash payment, rendering them
unimpaired.527 Holders of these claims are therefore not required to vote and are conclusively
presumed to accept the plan.
Section 1126 generally provides that each holder of a claim or interest of a class that is
impaired by a proposed plan may vote to accept or reject the plan.528 Impaired classes entitled to
vote on Purdue’s plan include Federal Government Unsecured claims,529 Non-Federal Domestic
Governmental claims, Tribe claims, Hospital claims, Third-Party Payor claims, Ratepayer claims,
NAS Monitoring claims,530 Personal Injury claims, and other general unsecured claims.531
Intercompany claims and interests held by co-debtors or affiliates are either unimpaired or impaired
with no distribution on account thereof and are either conclusively presumed to accept the plan
under §1126(f) or conclusively presumed to reject the plan under §1126(g).
Section 1126(g) provides that holders of a class is deemed to reject a plan that does not
provide the claim and interest holders with any property. Classes that will not receive anything under
the Debtors proposed plan and are therefore presumed to reject the plan include co-defendant
claims, claims subordinated under §§509(c) or 510 of the bankruptcy code,532 and all equity holders
of the Debtors.533
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At the time of the plan’s proposal, the Ad Hoc Committee, the Multi-State Governmental
Entity Group, the Native American Tribes Group, the Ad Hoc Group of Individual Victims, the Ad
Hoc Group of Hospitals, the Third-Party Payor Group, the Ratepayer mediation participants and
the NAS Committee all supported confirmation of the plan.534 The DOJ has issued a statement
confirming that the terms of the plan are consistent with its civil agreement and plea deal with
Purdue and that the terms of the plan meet the two conditions precedent to realizing the $1.775
billion judgment credit, creation of a public benefit company (NewCo) and distribution of $1.775
billion in value to state, tribal, or local governmental entity claimants (facilitated by various trusts).535
The OCC states that it is generally supportive of the primary economic terms and allocations in the
plan but identifies unresolved issues such as settlement guarantee mechanisms, governance of the
Master Disbursement Trust, the scope of releases granted, among other issues, that prevent the
committee from supporting the plan in its current form.536
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Road to Confirmation
The next step for Purdue is a hearing on its motion of an order approving the disclosure
statement, soliciting and voting procedures, and forms of ballots and notices.537 If this motion is
successful, Purdue will begin soliciting votes. Under §1129(a), Purdue will need to get at least one
class of claims that is impaired under the plan to accept the plan.538 Purdue will also need to show
that under the plan each creditor will receive more than they would in a chapter 7 liquidation.539 One
other major step for confirmation will be to convince the court that the proposed reorganization is
feasible, meaning Purdue will not need to engage in further liquidation or reorganization after
confirmation of the plan.540 Achieving confirmation of the proposed plan would be a big win for
Purdue, and achieve its main goals of consolidating litigation and imposing a settlement agreement
that will allow the shareholders (primarily the Sackler family) to walk away from the company in
exchange for the company’s assets and a cash payment. The plan is far from confirmed at this point,
however, and achieving confirmation will require lots of time, negotiations, and of course,
professional fees. The confirmation process in this case should provide a fascinating case study.
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Conclusion
Purdue’s reorganization has been both typical and unique thus far. Purdue’s reorganization
has been similar to other mass litigation driven bankruptcies as it seeks to consolidate litigation and
collectively settle personal injury claims. The lack of debtor financing required by Purdue is also not
unique among litigation driven bankruptcies, since many of these companies are profitable, the
problem is the injuries caused by their methods of achieving profits. Similarly, the establishment of
various trusts to pay out personal injury claimants is not unique among litigation driven
reorganizations. The massive professional fees generated are also typical and are a frequent cause of
criticism of the chapter 11 process.
This reorganization is unique, however, in the scope of its societal impact. The magnitude of
the opioid crisis that has its roots in Purdue’s marketing, manufacturing, and distribution of
Oxycontin puts a spotlight on this reorganization. The level of culpability of the company is also
unique, considering the criminal charges brought against Purdue by the United States Department of
Justice and the fact that many of the tort claimants are governmental entities. The spotlight on this
case will also subject the third-party releases sought by the Sackler family to intense scrutiny that
may change the way third-party releases are handled in bankruptcy cases. Purdue has a long road
ahead to complete its reorganization and it will be fascinating to watch how the reorganization
proceeds and what long term effects it may have on bankruptcy law in the United States.
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